Vol. 14 Issue 4 (2021)

VSKM 2021 N 4

PDF download Download the whole Issue

ORIGINAL RESEARCH

Assessment of fatigue and its impact on the well-being of bronchial asthma patients who were treated with specialized medical care Vizel A.A. (Russia, Kazan), Drent M. (Maastricht, Netherland), Vizel I.Yu. (Russia, Kazan), Vafina A.R. (Russia, Kazan), Shakirova G.R. (Russia, Kazan), Salakhova I.N. (Russia, Kazan), Kudryavtseva E.Z. (Russia, Kazan), Amirov N.B. (Russia, Kazan) P. 8

Clinical status and burden of atrial fibrillation in obese individuals: assessing the effects of body weight control programs Praskurnichy E.A. (Russia, Moscow), Morozova O.I. (Russia, Moscow) P. 15

Iron deficiency associations in patients with chronic heart failure Smirnova M.P. (Russia, Yaroslavl), Chizhov P.A. (Russia, Yaroslavl), Baranov A.A. (Russia, Yaroslavl), Ivanova Ju.I. (Russia, Yaroslavl), Medvedeva T.V. (Russia, Yaroslavl), Pegashova M.A. (Russia, Yaroslavl) P. 27

Market of oral antidiabetic drugs in the Republic of Crimea Sheikhmambetova L.N. (Russia, Simferopol), Egorova S.N. (Russia, Kazan), Egorova E. A. (Russia, Simferopol), Bekirova E.Yu. (Russia, Simferopol) P. 35

The effect of alpha-lipoic acid on the incidence of complications and consequences of myocardial infarction in patients with type II diabetes mellitus and diabetic polyneuropathy Yanovsky K.G. (Russia, Krasnodar) P .42

REVIEWS

Sarcoidosis. New COVID-19 infection and vaccination issues Vizel A.A. (Russia, Kazan), Vizel I.Yu. (Russia, Kazan), Kostinov M.P. (Russia, Moscow), Amirov N.B. (Russia, Kazan) P. 48

Diabetes mellitus and COVID-19. Features of the mutual influence of the two pandemics Kovalenko Ju.S. (Russia, Krasnodar), Ivanova L.A. (Russia, Krasnodar), Korol’ I.V. (Russia, Krasnodar), Bizheva T.V. (Russia, Krasnodar) P. 58

ORGANIZATION OF HEALTHCARE

Increasing the medical and social effectiveness of the preferential dental prosthetics program for certain categories of citizens in the Republic of Tatarstan Shaymieva N.I. (Russia, Kazan), Khasanov R.Sh. (Russia, Kazan), Olesova V.N. (Russia, Moscow) P. 67

PRACTICAL EXPERIENCE

An algorithm for morphological diagnosis of nodular growths in the thyroid gland (clinical experience) Zima D.V. (Russia, Simferopol), Bezrukov O.F. (Russia, Simferopol), Golubinskaya E.P. (Russia, Simferopol), Zyablitskaya E.Yu. (Russia, Simferopol), Makalish T.P. (Russia, Simferopol), Maximova Р.E. (Russia, Simferopol), Nepritimova E.A. (Russia, Simferopol) P .74

A current view of PFAPA-syndrome (Marshall syndrome) in children (clinical observation) Lutfullin I.Ya. (Russia, Kazan), Salugina S.O. (Russia, Moscow), Daminova M.A. (Russia, Kazan), Gazizov I.M. (Russia, Kazan) P. 78

CLINICAL CASE

New COVID-19 coronavirus infection in a patient with autoimmune polyglandular syndrome (clinical case) Ivanova L.A. (Russia, Krasnodar), Korol’ I.V. (Russia, Krasnodar), Kovalenko Ju.S. (Russia, Krasnodar), Ruzhitskaya L.V. (Russia, Krasnodar), Skibitskaya M.V. (Russia, Krasnodar), Petrovykh V.O. (Russia, Krasnodar), Tanin I.Yu. (Russia, Krasnodar) P. 86

ANNIVERSARIES

On the 60th anniversary of Andrey Yuryevich Anisimov, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Natural Sciences, Member of the editorial Board of the Journal «The Bulletin of Contemporary Clinical Medicine» P. 92

___

ORIGINAL RESEARCH

UDC 616.248-07:159.944.4

DOI: 10.20969/VSKM.2021.14(4).7-14

PDF download ASSESSMENT OF FATIGUE AND ITS IMPACT ON THE WELL-BEING OF BRONCHIAL ASTHMA PATIENTS WHO WERE TREATED WITH SPECIALIZED MEDICAL CARE

VIZEL ALEXANDER A., ORCID ID: 0000-0001-5028-5276; SPIN-code: 5918-5465; Author ID: 195447; D. Med. Sci., professor, the Head of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7 (987) 296-25-99, e-mail: lordara@inbox.ru

DRENT MARJOLEIN, ORCID ID: 0000-0003-1586-011; MD, PhD, professor, ILD Center of Excellence, Depertment of Pulmonology, St. Antonius Hospital, Nieuwegein, Koekoekslaan, 1, 3435 CM; ILD care foundation team, Ede; Department of Pharmacology and Toxicology, FHML, Netherland, Maastricht, tel. +3 (188) 320-14-82, e-mail: m.drent@antoniusziekenhuis.nl

VIZEL IRINA YU., ORCID ID: 0000-0002-8855-8177; SPIN-code: 6000-3813; Author ID: 246946; D. Med. Sci., professor of Russian Academy of Natural History; associate professor of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; researcher of Central Research Tuberculosis Institute, Russia, 107564, Moscow, Yauzskaya alley, 2, tel. +7(917)903-91-13, e-mail: tatpulmo@mail.ru

VAFINA ADELYA R., ORCID ID: 0000-0002-2157-9870; eLibrary SPIN-code: 8498-7881; Author ID: 57213618417; postgraduate student of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(960)054-03-64, e-mail: adelyavafina@gmail.com

SHAKIROVA GULNAZ R., ORCID ID: 0000-0003-3254-5219; C. Med. Sci., assistant of professor of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(917) 84-30-39, e-mail: adeleashakirova@mail.ru

SALAKHOVA IRINA N., ORCID ID: 0000-0001-8539-4413; SPIN-code 3990-0732; Author ID: 1039324; postgraduate student of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(937)283-32-25, e-mail: iboroznova@gmail.com

KUDRYAVTSEVA ELVIRA Z., the Head of the Department of pulmonology of City Clinical Hospital No 16 of Kazan, Russia, 420039, Kazan, Gagarin str., 121, tel. +7(917)269-68-88, e-mail: elk-a@mail.ru

AMIROV NAIL B., ORCID ID: 0000-0003-0009-9103; SCOPUS Author ID: 7005357664; D. Med. Sci., academician of RAE, professor of the Department of outpatient therapy and general medical practice of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(905)313-01-11, e-mail: namirov@mail.ru

Abstract. Aim. To assess the prevalence of fatigue in bronchial asthma patients by using the FAS (Fatigue Assessment Scale) questionnaire, and to evaluate the status of patients with bronchial asthma who experience fatigue. Material and methods. We examined 458 patients with bronchial asthma: 312 (68,81%) female and 146 (31,9%) males, aged 18 to 87 years, who were seen by pulmonologists and allergists. The median age was 60,0. The history was collected, bronchial asthma control questionnaires were lled out, FAS, physical examination, spirometry, and pulse oximetry were performed. Laboratory data were taken from medical records. Electronic patient database creation and statistical processing were performed using SPSS­18 program in Windows­10 medium. Results and discussion. Among the patients examined, 74,5% had severe bronchial asthma and 87,8% had uncontrolled bronchial asthma. Only 29,7% of patients have not been hospitalized within the last year. Decrease of forced expiratory volume 1 below the norm (80% of its due) was observed in 63.5% of the examined patients. Fatigue detected by FAS questionnaire was 4 times more frequent in hospitalized patients, in those supervised by pulmonologists (2,5 times), in persons with excessive body weight, in those with uncontrolled bronchial asthma, with a severe disease course, in persons with 3 or more exacerbations per year and with at least one hospital admission. They were almost 3 times more likely to have forced mid­ expiratory ow rate decrease below the norm, and 2 times more likely to have a lower forced expiratory volume 1. They were more frequently treated with short­acting bronchodilators, inhaled glucocorticosteroids/LABAs, and almost 6 times more frequently with systemic glucocorticosteroids. Conclusion. Detection of fatigue by the FAS questionnaire in patients with AD is an independent criterion of decreased quality of life, associated with many clinical and functional characteristics of the disease.

Key words: bronchial asthma, fatigue, FAS (Fatigue Assesment Scale).

For reference: Vizel AA, Drent M, Vizel IYu, Va na AR, Shakirova GR, Salakhova IN, Kudryavtseva EZ, Amirov NB. Assessment of fatigue and its impact on the well­being of bronchial asthma patients who were treated with specialized medical care. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 7­14. DOI: 10.20969/VSKM.2021.14(4).7­14.

References

  1. Vafin AYu, Vizel AA, Sherputovsky VG, Lysenko GV, Kolgin RA, Vizel IYu, Shaymuratov RI, Amirov NB. Zabolevanija organov dyhanija v Respublike Tatarstan: mnogoletnij jepidemiologicheskij analiz [Respiratory diseases in tatarstan: perennial epidemiological analysis]. Vestnik sovremennoj klinicheskoj mediciny [The Bulletin of Contemporary Clinical Medicine]. 2016; 9 (1): 24—31.

  2. Janson C, Johannessen A, Franklin K, Svanes C, Schiöler L, Malinovschi A, Gislason T, Benediktsdottir B, Schlünssen V, Jõgi R, Jarvis D, Lindberg E. Change in the prevalence asthma, rhinitis and respiratory symptom over a 20 year period: associations to year of birth, life style and sleep related symptoms. BMC Pulm Med. 2018; 18(1):152. DOI: 10.1186/s12890­018­0690­9.

  3. Gaffney AW, Himmelstein DU, Christiani DC, Woolhand­ ler S. Socioeconomic inequality in respiratory health in the US from 1959 to 2018. JAMA Intern Med. 2021. DOI: 10.1001/jamainternmed.2021.2441.

  4. Van Herck M, Spruit MA, Burtin C, Djamin R, Antons J, Goërtz YMJ, Ebadi Z, Janssen DJA, Vercoulen JH, Peters JB, Thong MSY, Otker J, Coors A, Sprangers MAG, Muris JWM, Wouters EFM, van ‘t Hul AJ. Fatigue is highly prevalent in patients with asthma and contributes to the burden of disease. J Clin Med. 2018; 7(12): 471. DOI: 10.3390/jcm7120471.

  5. Zampogna E, Centis R, Negri S, Fiore E, Cherubino F, Pignatti P, Hef er E, Canonica GW, Sotgiu G, Saderi L, Migliori GB, Spanevello A, Visca D. Effectiveness of pulmonary rehabilitation in severe asthma: a retrospective data analysis. J Asthma. 2020; 57(12): 1365­1371. DOI: 10.1080/02770903.2019.1646271.

  6. Kleijn WPE, De Vries J, Wijnen PAHM., Drent M. Minimal (clinically) important differences for the Fatigue Assessment Scale in sarcoidosis. Respir Med. 2011; 105: 1388­1395.

  7. Chuchalin AG, Ajsanov ZR, Chikina SJu, et al. Federal’nye klinicheskie rekomendacii po ispol’zovaniju metoda spirometrii [Federal clinical guidelines for the use of the spirometry method]. Moskva: Rossijskoe respiratornoe obshhestvo [Moscow: Russian Respiratory Society]. 2013; 21 p.

  8. Michielsen HJ, De Vries J, Van Heck GL. Psychometric qualities of a brief self­rated fatigue measure: The Fatigue Assessment Scale. J Psychosom. Res. 2003; 54(4): 345­ 352. DOI: 10.1016/s0022­3999(02)00392­6.

  9. Nasledov AD. SPSS 19: professional’nyj statisticheskij analiz dannyh [SPSS 19: Professional Statistical Data Analysis.]. SPb: Piter [SPb: Peter]. 2011; 416 p.

  10. Fletcher R, Fletcher S, Vagner Je. Klinicheskaja jepidemiologija: Osnovy dokazatel’noj mediciny. Moskva: Media Sfera. 1998; 353 p.

  11. Narkevich AN, Vinogradov KA. Metody opredelenija minimal’no neobhodimogo ob#ema vyborki v medicinskih issledovanijah [Methods for determining the minimum required sample size in medical research]. Social’nye aspekty zdorov’ja naselenija [Social aspects of population health]. 2019; 65(6): 10. DOI: 10.21045/2071­5021­2019­ 65­6­10.

  12. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention, 2021. Availaible from: www. ginasthma.org

  13. Perel’man NL, Kolosov VP. Mnogoletnjaja dinamika kachestva zhizni, svjazannogo so zdorov’em, u bol’nyh bronhial’no astmo [Long­term dynamics of health­ related quality of life in patients with bronchial asthma]. Pul’monologija [Pulmonology]. 2018; 28 (6): 708–714. DOI: 10.18093/0869­0189­2018­28­6­708­714

  14. Günaydın FE, Ediger D, Erbay M. Fatigue: A forgotten symptom of asthma. Clin Respir J. 2021. doi: 10.1111/ crj.13356.

  15. Drent M, Lower EE, De Vries J. Sarcoidosis­associated fatigue. Eur Respir J. 2012; 40 (1): 255­263. DOI: 10.1183/09031936.00002512.

  16. Baptist AP, Busse PJ. Asthma over the age of 65: All’s well that ends well. J Allergy Clin Immunol Pract. 2018; 6 (3): 764­773. DOI: 10.1016/j.jaip.2018.02.007.

  17. Small SP, Lamb M. Measurement of fatigue in chronic obstructive pulmonary disease and in asthma. Int J Nurs Stud. 2000; 37 (2): 127­133. DOI: 10.1016/s0020­ 7489(99)00066­8.

 

UDC 616.12-008.313.2-07:616-056.52

DOI: 10.20969/VSKM.2021.14(4).15-26

PDF download CLINICAL STATUS AND BURDEN OF ATRIAL FIBRILLATION IN OBESE INDIVIDUALS: ASSESSING THE EFFECTS OF BODY WEIGHT CONTROL PROGRAMS

PRASKURNICHY EVGENY A., ORCID ID: 0000-0002-9523-5966; D. Med. Sci., professor of the Department of aviation and space medicine of Russian Medical Academy of Continuous Profesional Education, Russia, Moscow, 123995, Barrikadnaya str., 2/1, tel. 8-916-524-84-81, e-mail: praskurnichey@mail.ru

MOROZOVA OLGA I., ORCID ID: 0000-0002-0366-4764; postgraduate student of the Department of internal medicine of State Research Center Federal Medical Biophysical Center named after A.I. Burnazyan, Russia, 123098, Moscow, Zhivopisnaya str., 46, tel. 8-963-770-60-39, e-mail: dr.morozova@bk.ru

Abstract. Background. Correction of modi able risk factors is the most promising direction of modern scienti c research in the eld of atrial brillation. Aim. To assess the impact of primary obesity and the implementation of weight loss programs on the burden of atrial brillation. Material and methods. The study involved 162 patients with paroxysmal or persistent atrial brillation. Study design: prospective cohort study. Patients were divided into two groups based on body weight at the moment of study inclusion: patients with normal body mass index and patients with 1–3­degree obesity. Control medical examinations were performed at least once every 2 months for at least 36 months. Based on the clinical picture of the disease and data of Holter electrocardiogram monitoring for 7 days, which was performed when the patients presented complaints, or routinely every 6 months, changes in the form of the disease were registered. Results and discussion. Throughout the study, different dynamics of body weight were observed in the patient groups. Regression of atrial brillation from persistent to paroxysmal form, as well as spontaneous recovery of sinus rhythm against the background of modi cation of other risk factors were registered in all groups, except for the group of patients with obesity and body weight increase by 3% or more during the study, and were signi cantly more common among patients who kept initial normal weight or reduced it with obesity by 3% or more by the end of the study. In addition, greater need and frequency of interventional treatment was demonstrated in the group of obese patients who increased their body weight by 3% or more compared with the group of obese patients who decreased their body weight by 3% or more throughout the study [(p=0,0079*) and (p=0,0374*), respectively)]. Conclusion. The present study demonstrates the effect of primary obesity and body weight dynamics on the burden of atrial brillation. Obesity is directly associated with a higher percentage of persistent atrial brillation despite correction of other signi cant risk factors. Body weight reduction in obese patients not only slows down the natural progression of atrial brillation and reduces the severity of its symptoms, but is also a signi cant predictor of the regression of the disease in terms of both the form of arrhythmia (transformation of persistent atrial brillation into paroxysmal) and the spontaneous recovery of sinus rhythm. Reduction of body weight by 3% or more in obese patients leads to increased ef ciency and ef cacy of interventional treatment.

Key words: atrial brillation, the burden of atrial brillation, sinus rhythm recovery, obesity, body weight control, interventional treatment.

For reference: Praskurnichy EA, Morozova OI. Clinical status and burden of atrial brillation in obese patients: assessing the effects of body weight control programs. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 15­26. DOI: 10.20969/VSKM.2021.14(4).15­26.

References

1. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial brillation developed in collaboration with the European Association of Cardio­Thoracic Surgery (EACTS). The European Heart Journal. 2021; 42 (5): 373­498.

2. Revishvili ASh, Rzaev FG, Gorev MV, et al. Diagnostika i lechenie brillyacii predserdij; Klinicheskie rekomendacii [Diagnosis and treatment of atrial fibrillation; Clinical guidelines]. Moskva [Moscow]. 2017; 201 p.

3. Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial brillation: a longitudinal cohort study of 21 years. The European Heart Journal. 2008; 29 (18): 2227­2233.

4. Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2008; 11 (4): 423­434.

5. Bokeriya LA, Bokeriya OL, Gluhova EZ, et al. Fibrillyaciya predserdij; Klinicheskie rekomendacii [Atrial brillation; Clinical guidelines]. Moskva [Moscow]. 2017; 65 p.

6. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014; 384 (9945): 766­781.

7. Nalliah C, Sanders P, Kottkamp H, et al. The role of obesity in atrial brillation. The European Heart Journal. 2016; 37 (20): 1565­1572.

8. Auer J. Fat: an emerging player in the eld of atrial bril­ lation. European Heart Journal. 2016; 38 (1): 62­65. doi: 10.1093/eurheartj/ehw013.

9. Dedov II, Mokrysheva NG, Mel’nichenko GA, et al. Ozhirenie; Klinicheskie rekomendacii Ministerstva zdra­ voohraneniya Rossijskoj Federacii [Obesity; Clinical guidelines]. Moskva [Moscow]. 2020; 43 p.

10. Wong CX, Sullivan T, Sun MT, et al. Obesity and the Risk of Incident, Post Operative, and Post­Ablation Atrial Fibrillation: A Meta­Analysis of 626, 603 Individuals in 51 Studies. Journal of the American College of Cardiology: Сlinical electrophysiology. 2015; 1 (3): 139–152.

11. Garvey WT, Mechanick JI, Brett EM, Garber AJ, et al. Reviewers of the AACE/ACE Obesity Clinical Practice Guidelines. American Association of Clinical Endocrinologists and American College of Endocrinologycomprehensive clinical practice guidelines for medicalcare of patients with obesity. Endocrine Practice. 2016; 22 (3): 1­203.

12. Shlyahto EV, Nedogoda SV, Konradi AO, et al. Diagnostika, lechenie, pro laktika ozhireniya i associirovannyh s nim zabolevanij; Nacional’nye klinicheskie rekomendacii [Diagnosis, treatment, prevention of obesity and associa­ ted diseases; National clinical guidelines]. Sankt­Peterburg [Saint Petersburg]. 2017; 164 p.

13. Bondarenko IZ, Butrova SA, Goncharov NP, et al. Lechenie morbidnogo ozhireniya u vzroslyh; Nacional’nye klinicheskie rekomendacii [Treatment of morbid obesity in adults; National clinical guidelines]. Ozhirenie i metabolizm [Obesity and metabolism]. 2011; 3: 75­83.

14. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Journal of the American College of Cardiology. 2014; 63(25): 2985–3023.

15. Arakelyan MG, Bokeriya LA, Vasil’eva EYu, et al. Fibrillyaciya i trepentanie predserdij; Klinicheskie rekomendacii [Atrial fibrillation and flutter; Clinical guidelines of the Ministry of Health of the Russian Federation]. Moskva [Moscow]. 2020; 185 p.

16. Filatov AG, Tarashvili EG. Epidemiologiya i social’naya znachimost’ brillyacii predserdij [Epidemiology and social signi cance of atrial brillation]. Annaly aritmologii [Annals of Arrhythmology]. 2012; 9 (2): 5­13.

17. Goluhova EZ, Gromova OI, Bulaeva NI, et al. Epikardial’nyzhir i brillyaciya predserdi : rol’ pro brogennyh mediatorov [Epicardial fat and atrial brillation: the role of pro brogenic mediators]. Kardiologiya [Cardiology]. 2018; 58 (7): 59–65.

18. Golicyn SP, Panchenko EP, Kropacheva ES, et al. Diagnostika i lechenie brillyacii predserdij [Diagnosis and treatment of atrial brillation]. Evrazijskij kardiologicheskij zhurnal [Eurasian Journal of Cardiology]. 2019; 4: 4­85.

19. Podzolkov VI, Tarzimanova AI, Gataulin RG, et al. Rol’ ozhireniya v razvitii brillyacii predserdij: sovremennoe sostoyanie problemy [The role of obesity in the develop­ ment of atrial brillation: the current state of the problem]. Kardiovaskulyarnaya terapiya i pro laktika [Cardiovascular therapy and prevention]. 2019; 18 (4): 109­114.

20. Lakkireddy DR, Blake GE, Patel D, Rotter M, et al. Success of Radiofrequency Catheter Ablation of Atrial Fibrillation: Does Obesity In uence the Outcomes? Journal of Atrial Fibrillation. 2008; 1 (1): 7­13.

21. Pathak RK, Middeldorp ME, Lau DH, et al. Aggressive risk factor reduction study for atrial brillation and implications for the outcome of ablation: the ARREST­AF cohort study.Journal of the American College of Cardiology. 2014; 64 (21): 2222­2231.

22. Winkle RA, Mead RH, Engel G, Kong MH, Fleming W, et al. Impact of obesity on atrial brillation ablation: patient characteristics, long­term outcomes, and complications. Heart Rhythm. 2017; 14: 819­827.

23. Calkins H, Hindricks G, Cappato R, et al. Guideline 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensusstatement on catheter and surgical ablation of atrialbrillation: Executive summary. Journal of Arrhythmia. 2017; 33: 369–409.

 

UDC 616.12-008.46-036.12-07:616.152.72-074

DOI: 10.20969/VSKM.2021.14(4).27-34

PDF download IRON DEFICIENCY ASSOCIATIONS IN PATIENTS WITH CHRONIC HEART FAILURE

SMIRNOVA MARINA P., ORCID ID: 0000-0002-8988-998X; C. Med. Sci., associate professor of the Department of internal medicine of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5, tel. +7(910)975-48-72, e-mail: msm76-743@yandex.ru

CHIZHOV PETR A., ORCID ID: 0000-0001-7969-6538; D. Med. Sci., professor, the Head of the Department of internal medicine of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5
BARANOV ANDREY A., ORCID ID: 0000-0001-7847-1679; D. Med. Sci., professor, Vice-Rector on research and development of Regional Health; the Head of the Department of outpatient medicine, clinical laboratory diagnostics and medical biochemistry of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5

IVANOVA JULIA I., ORCID ID: 0000-0001-6349-4587; C. Med. Sci., associate professor of the Department of internal medicine of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5

MEDVEDEVA TATIANA V., ORCID ID: 0000-0001-7603-1610; C. Med. Sci., assistant of professor of the Department of internal medicine of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5

PEGASHOVA MARINA A., ORCID ID: 0000-0002-5617-1197; assistant of professor of the Department of internal medicine of Yaroslavl State Medical University, Russia, 150000, Yaroslavl, Revolyutsionnaya str., 5

Abstract. Background. Iron de ciency is a frequent comorbid condition in patients with chronic heart failure. At the same time, the factors contributing to iron de ciency in these patients are poorly understood. Aim. The aim of the study was to establish the spectrum of factors associated with iron de ciency in patients with chronic heart failure. Material and methods. We examined 294 patients [mean age (71,29±8,06) years] with chronic heart failure: 213 patients with iron de ciency and 81 patients without such. All patients were examined on the subject of presence, duration and severity of comorbid conditions, medication history, clinical examination, echocardiography, complete blood count, biochemical studies with determination of iron level, ferritin, transferrin, transferrin saturation with iron, soluble transferrin receptors, hepcidin, and erythropoietin, routine laboratory test results, presence and severity of asthenia, anxiety, or depression. Two statistical methods were applied to evaluate the association of the studied indexes with iron de ciency. Statistical data analysis was performed using Stata/MP version 14.0 (StataCorp Enhancements, TX 77845, USA) and MedCalc Statistical Software version 18.2.1 (MedCalc Software bvba, Ostend, Belgium; 2018. Results and discussion. It was found that iron de ciency in patients with chronic heart failure was signi cantly associated with functional class III–IV and stages IIb–III of the disease, longer history of hypertension, diabetes mellitus, and with age. In addition, iron de ciency was signi cantly associated with a history of using antiaggregant agents, angiotensin­converting enzyme inhibitors, new oral anticoagulants, severity of renal damage, asthenia, anxiety and depression, decreased serum iron and hemoglobin levels, decreased transferrin iron saturation and mean erythrocyte hemoglobin content, increased hepcidin and erythropoietin levels for over 1 year. Conclusion. Iron de ciency in patients with chronic heart failure is signi cantly associated with numerous clinical and laboratory factors, in particular with the severity of heart failure, duration and severity of comorbid diseases, medication history, decreased serum iron levels and transferrin iron saturation, increased hepcidin and erythropoietin concentrations.

Key words: chronic heart failure, iron de ciency, associations with iron de ciency.

For reference: Smirnova MP, Chizhov PA, Baranov AA, Ivanova YuI, Medvedeva TV, Pegashova MA. Iron de ciency associations in patients with chronic heart failure. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 27­34. DOI: 10.20969/VSKM.2021.14(4).27­34.

References

1. Kurz K, Lanser L, Seifert M, Kosher F, Pölzl G, Weiss G. Anaemia, iron status, and gender predict the outcome in patients with chronic heart failure. ESC Heart Failure 2020; 7: 1880–1890. DOI: 10.1002/ehf2.12755

2. Moliner P, Enjuanes C, Tajes M, Cainzos­Achirica M, Lup J, Garay A, et al. Association Between Norepinephrine Levels and Abnormal Iron Status in Patients With Chronic Heart Failure: Is Iron De ciency More Than a Comorbidity? J Am Heart Assoc. 2019; 8 (4): e010887. DOI: 10.1161/ JAHA.118.010887.

3. Beattie JM, Khatib R, Phillips CJ, Williams SJ. Iron de ciency in 78 805 people admitted with heart failure across England: a retrospective cohort study. Open Heart. 2020; 7 (1): e001153. DOI: 10.1136/openhrt­2019­001153.

4. Jankowska EA, von Haehling S, Anker SD, Macdougall IC, Ponikowski P. Iron de ciency and heart failure: diagnostic dilemmas and therapeutic perspectives. Eur Heart J. 2013; 34 (11): 816­829. DOI: 10.1093/eurheartj/ehs224.

5. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H. Ferric carboxymaltose in patients with heart failure and iron de ciency. N Engl J Med 2009; 361: 2436.

6. Van der Wal HH, van Deursen VM, van der Meer P, Voors AA. Comorbidities in Heart Failure. Handb Exp Pharmacol. 2017; 243: 35­66. DOI: 10.1007/164_2017_27. Von Haehling S, Ebner N, Evertz R, Ponikowski P,

7. Anker SD. Iron De ciency in Heart Failure: An Overview. JACC Heart Fail. 2019; 7 (1): 36­46. DOI: 10.1016/j. jchf.2018.07.015

8. Vatutin NT, Taradin GG, Kanisheva IV, Venzhega VV. Anemija i zhelezodeficit u bol’nyh s hronicheskoj serdechnoj nedostatochnost’ju [Anemia and iron de ciency in patients with chronic heart failure]. Kardiologija [Cardiology]. 2019; 59 (4): 4­20.

9. Nagueh SF, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, et al. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 29 (4): 277­314. DOI: 10.1016/j.echo2016.01.011.

10.Lang RM, Badano LP, Mor­Avi V, A lalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quanti cation by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr. 2016; 28 (1): 1­39. DOI: 10.1016/j. echo.2014.10.003.

11. ESC GUIDELINES. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur J Heart Fail. 2016; 18 (8): 891­975.

12. VertkinAL,SkotnikovAS.Neobhodimost’korrekciide cita zheleza u pacientov, dlitel’noe vremja poluchajushhih antiagregantnuju terapiju [The necessity to correct iron de ciency in patients receiving antiplatelet therapy for a long time]. Lechashhij vrach [Attending doctor]. 2012; 2: 23­28.

13. StuklovNI.De citzhelezaianemijaubol’nyhhronicheskoj serdechnoj nedostatochnost’ju [Iron de ciency and anemia in patients with chronic heart failure]. Racional’naja farmakoterapija v kardiologii [Rational pharmacotherapy in cardiology]. 2017; 13 (5): 651­660. DOI: 10.20996/1819­ 6446­2017­13­5­651­660

14. Ishani A, Weinhandl E, Zhao Z, Gilbertson DT, Collins AJ, Yusuf S, et al. Angiotensin­converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. J Am Coll Cardiol. 2005; 45 (3): 391­399. DOI: 10.1016/j.jacc.2004.10.038.

15. Silverberg D, Wexler D, Schwartz D. Is Correction of Iron De ciency a New Addition to the Treatment of the Heart Failure? International Journal of Molecular Sciences. 2015; 16 (12): 14056–14074. DOI: 10.3390/ ijms160614056

16. Tang YD, Katz SD, Anand IS. Pathogenesis of anemia in cardiorenal disease. Rev Cardiovasc Med. 2005; 6 (Suppl 3): 13­21.

17. Anand IS, Gupta P. Anemia and Iron De ciency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018; 138 (1): 80­98. DOI: 10.1161/ CIRCULATIONAHA.118.030099.

18. Stewart R, Hirani V. Relationship Between Depressive Symptoms, Anemia, and Iron Status in Older Residents From a National Survey Population. Psychosomatic medicine. 2012; 74. 208­13. DOI: 10.1097/PSY.0b013e3182414f7d.

19. Rukavicyn OA. Anemii; 2­e izdanie [Anemias; 2nd edition]. Moskva: GEOTAR­Media [Moscow: GEOTAR­Media]. 2016; 250 p.

20. Solomahina NI, Nahodnova ES, Ershov VI, Belenkov JuN. Rol’ gepsidina v formirovanii anemii hronicheskih zabolevanij i zhelezodeficitnoj anemii u bol’nyh s hronicheskoj serdechnoj nedostatochnost’ju v pozhilom i starcheskom vozraste [The role of hepcidin in the formation of anemia of chronic diseases and iron de ciency anemia in patients with chronic heart failure in old and senile age]. Kardiologija [Cardiology]. 2018; 58 (3): 20–27. DOI: 10.18087/cardio.2018.3.1009.

21. Makarova NA. Puti korrekcii dizreguljacii jeritropojeza pri ishemicheskoj bolezni serdca [Ways of correcting erythropoiesis dysregulation in ischemic heart disease]. Klinicheskaya medicina [Clinical medicine]. 2013; 91 (1): 28­31.

 

UDC 615.252.349.7:33(477.75)

DOI: 10.20969/VSKM.2021.14(4).35-41

PDF download MARKET OF ORAL ANTIDIABETIC DRUGS IN THE REPUBLIC OF CRIMEA

SHEIKHMAMBETOVA LILYA N., ORCID ID: 0000-0002-4481-2225; assistant of professor of the Department of pharmacy of Medical academy named after S.I. Georgievskiy of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7, tel. +7(978)758-00-46, e-mail: lilya.rojz@mail.ru

EGOROVA SVETLANA N., ORCID ID: 0000-0001-7671-3179; D. Pharm. Sci., professor, deputy director for educational activities of Institute of pharmacy of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. 8(843)521-44-96, e-mail: svetlana.egorova@kazangmu.ru

EGOROVA ELENA A., ORCID ID: 0000-0003-4012-2523; C. Pharm. Sci., associate professor of the Department of basic and clinical pharmacology of Medical academy named after S.I. Georgievskiy of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7, tel. +7(978)859-48-60, e-mail: elena212007@rambler.ru

BEKIROVA ELVIRA YU., ORCID ID: 0000-0003-4097-2376; C. Med. Sci., associate professor of the Department of dermatovenereology and cosmetology of Medical academy named after S.I. Georgievskiy of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7, tel. +7(978)-755-04-34, e-mail: elvira8300@mail.ru

Abstract. Background. Diabetes mellitus is one of the most signi cant social problems of public health. The main pathogenetic factors in the development of type 2 diabetes mellitus are a decrease in insulin synthesis by β­cells of Langerhans islets or impaired insulin receptor sensitivity to insulin, which leads to a high risk of insulin resistance and β­cell dysfunction. Aim. The aim of the study was to investigate and analyze the assortment of hypoglycemic drugs presented on the pharmaceutical market of the Republic of Crimea. Material and methods. Materials for the studyserved as a range of antidiabetic drugs presented in the pharmacy organization «Apteka Martana» LLC, specializing in drug supply of outpatients with diabetes mellitus. Results and discussion. A large share in the assortment of hypoglycemic drugs of a specialized pharmacy organization is occupied by groups of biguanides (25,5%), sulfonylurea derivatives (23,6%) and combined oral hypoglycemic agents (23%), among which the most widespread is the combined drug containing glibenclamide and metformin. Analysis of antidiabetic drugs by manufacturer revealed the prevalence of domestically produced drugs on the pharmaceutical market (52%). At the same time, antidiabetic drugs of foreign manufacturers occupy 48% and are imported into the Russian Federation by 27 manufacturers from 17 countries. Calculation of the index of renewal and completeness of use of the range of antidiabetic drugs revealed high levels of these indicators, which allows the provision of the most relevant medicines with proven ef cacy and safety to patients with diabetes mellitus. Conclusion. The pharmaceutical market of hypoglycemic drugs presented in the Republic of Crimea is characterized by a suf cient assortment and high demand for drugs of different groups, which makes it possible to conduct generic substitutions in accordance with the capabilities and needs of patients.

Key words: diabetes mellitus, oral hypoglycemic drugs, assortment.

For reference: Sheikhmambetova LN, Egorova SN, Egorova EA, Bekirova EYu. Market of oral antidiabetic drugs in the Republic of Crimea. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 35­41.DOI: 10.20969/VSKM.2021.14(4).35­41.

References

  1. Khursheed R, Singh SK, Wadhwa S, et al. Treatment strategies against diabetes: Success so far and challenges ahead. Eur J Pharmacol. 2019; 862: 172625. DOI: 10.1016/j.ejphar.2019.172625.

  2. IFD Diabetes atlas. 9th edition 2019. Available at: https:// diabetesatlas.org/en/

  3. Wong CY, Al­Salami H, Dass CR. Potential of insulinnanoparticle formulations for oral delivery and diabetestreatment. J Control Release. 2017; 264: 247­275. DOI: 10.1016/j.jconrel.2017.09.003.

  4. Padhi S, Nayak AK, Behera A. Type II diabetes mellitus: a review on recent drug based therapeutics. Biomed Pharmacother. 2020; 131: 110708. DOI: 10.1016/j. biopha.2020.110708.

  5. Grover M, Utreja P. Recent advances in drug delivery systems for anti­diabetic drugs: a review. Curr Drug Deliv. 2014; 11 (4): 444­457. DOI: 10.2174/156720181166614 0118225021.

  6. Chung IM, Rajakumar G, Subramanian U, et al. Insightson the current status and advancement of diabetesmellitus type 2 and to avert complications: An overview. Biotechnol Appl Biochem. 2020; 67 (6): 920­928. DOI: 10.1002/bab.1853.

  7. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of adolescents and youth with recent­onset type 2 diabetes: the TODAY cohort at baseline. J Clin Endocrinol Metab. 2011; 96 (1): 159­167. DOI: 10.1210/jc.2010­1642.

  8. Rangel ÉB, Rodrigues CO, de Sá JR. Micro­ and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies. J Diabetes Res. 2019; 2019: 2161085. DOI: 10.1155/2019/2161085.

  9. Lipscombe L, Booth G, Butalia S, et al. Pharmacologic Glycemic Management of Type 2 Diabetes in Adults. Can J Diabetes. 2018; 42 (1): S88­S103. DOI: 10.1016/j. jcjd.2017.10.034.

  10. Dedov II, Shestakova MV, Majorov Ayu, ed. Algoritmy specializirovannoj medicinskoj pomoshchi bol’nym saharnym diabetom [Algorithms of specialized medical care for patients with diabetes mellitus]. Sakharni diabet [Diabetes mellitus]. 2019; 22 (1S1): 1­144. DOI: 10.14341/ DM221S1.

11. Prikaz Ministerstva zdravoohraneniya Rossijskoj Federacii ot 01.10.2020 No 1054n «Ob utverzhdenii standartov medicinskoj pomoshchi vzroslym pri saharnom diabete 2 tipa» [Order of the Ministry of Health of the Russian Federation dated 01.10.2020 No. 1054n «On approval of standards of medical care for adults with type 2 diabetes mellitus»].

12. Chaudhury A, Duvoor C, Reddy Dendi VS, et al. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front Endocrinol (Lausanne). 2017; 8: 6. DOI: 10.3389/fendo.2017.00006.

13. Gosudarstvennyj reestr lekarstvennyh sredstv Rossii [State Register of Medicines of Russia]. URL: http://www. grls.rosminzdrav.ru/Default.aspx.

14. Cosentino F, Grant PJ, Aboyans V, et al. 2019 Reko­ mendatsii YeSC/EASD po sakharnomu diabetu, prediabetu i serdechno­sosudistym zabolevaniyam [2019 ESC / EASD Guidelines for Diabetes Mellitus, Prediabetes and Cardiovascular Disease]. Rossiyskiy kardiologicheskiy zhurnal [Russian journal of cardiology]. 2020; 25 (4): 3839.DOI: 10.15829/1560­4071­2020­3839

15. Sidullin AYu. Strukturnyj analiz assortimenta lekarst­ vennyh sredstv, primenyaemyh pri detoksikacionnoj terapii v narkologii na regional’nom urovne (na primere Respubliki Tatarstan) [Structural analysis of the range of drugs used in detoxi cation therapy in narcology at the regional level (on the example of the Republic of Tatarstan)]. Fundamental’nye issledovaniya [Basic research]. 2013; 11 (5): 964­969.

16. Ekonomika farmacii; Organizaciya deyatel’nosti apteki [Economics of Pharmacy. Organization of pharmacy activities]. URL: copharmacia.ru/publ/farmacevticheskij_ marketing/marketing_osnovy/osnovnye_pokazateli_ assortimenta_aptechnoj_organizacii/15­1­0­1104.

17. Gerasimenko NM, Toropova TA. Podhod k ocenke konkurentnogo polozheniya torgovoj organizacii cherez vyvedenie racional’nosti assortimenta [Approach toassessing the competitive position of a trade organizationthrough the derivation of the rationality of the assortment]. Sovremennaya ekonomika: problemy, tendencii, per­ spektivy [Modern economy: problems, trends, prospects]. 2013; 9: 170­188.

18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood­glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352 (9131): 854­865.

19. Varvaki RD, Catani PL, Reck RL, et al. The Association between Sulfonylurea Use and All­Cause and Cardiovascular Mortality: A Meta­Analysis with Trial Sequential Analysis of Randomized Clinical Trials. PLoS Med. 2016; 13 (4): e1001992. DOI: 10.1371/ journal.pmed.1001992.

20. Rosenstock J, Kahn SE, Johansen OE et al. CAROLINA Investigators. Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA. 2019; 322 (12): 1155­1166. DOI: 10.1001/ jama.2019.13772.

 

UDC 616.127-005.8: 616.379-008.64-085.356:577.164.186

DOI: 10.20969/VSKM.2021.14(4).42-47

PDF download THE EFFECT OF ALPHA-LIPOIC ACID ON THE INCIDENCE OF COMPLICATIONS AND CONSEQUENCES OF MYOCARDIAL INFARCTION IN PATIENTS WITH TYPE II DIABETES MELLITUS AND DIABETIC POLYNEUROPATHY

YANOVSKY KONSTANTIN G., ORCID ID: 0000-0002-2355-4407; postgraduate student of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, e-mail: yanovsky.endokrd@yandex.ru

Abstract. Background. Type II diabetes mellitus poses numerous negative factors affecting the course of myocardial infarction, including both metabolic indicators (glycated hemoglobin levels, lipid spectrum indicators) and neurological factors (severity of diabetic polyneuropathy, including cardiac autonomic neuropathy). Aim. The aim of the study was to evaluate the effect of alpha­lipoic acid on the incidence and consequences of myocardial infarction in patients with type II diabetes mellitus and diabetic polyneuropathy. Material and methods. The study group included 100 people aged 60–75 years old with the existing diagnosis of diabetes mellitus determined according to available documents and myocardial infarction determined according to clinical manifestations, increased levels of CPK, CPK­MB, Troponin­T, presence of ST­segment elevation and Q­wave on ECG performed according to the standard protocol in 12 leads. Streptokinase, zofenopril, metoprolol XR, atorvastatin, clopidogrel, and acetylsalicylic acid were used as therapy for myocardial infarction in all patients. Soluble insulin (Vozulim), and medium­acting insulin (Rinsulin NPX) were used as therapy for diabetes mellitus. Study protocol: First examination included assessment of clinical symptoms of myocardial infarction and diabetic polyneuropathy by NSS scale, standard ECG was performed, ECHO­CG was performed according to standard protocol, ejection fraction over 55% for further statistical analysis was taken as equal to 55%. Cardiac contractility, signs of myocardial hypertrophy and rhythm disturbances were assessed. Valsalva and 30:15 tests were performed to assess the functional state of the heart. Laboratory examination included CPK MB, Troponin­T level, glycemic control (glycemic pro le), HbA1C level, and lipid spectrum assessment. The obtained data were processed using Statistica 10 program, and Microsoft Excel 2010. The differences were considered statistically signi cant atp<0,05. Results and discussion. Application of alpha­lipoic acid in combination with standard treatment of myocardial infarction and maintenance of target glycemic levels leads to improvement of functional myocardial parameters, metabolic parameters of carbohydrate and partially lipid metabolism, as well as to reduction of rhythm disturbances incidence. The mean ejection fraction index increases as well. The results con rm the possibility of prescribing alpha­lipoic acid to patients with myocardial infarction and type II diabetes associated with diabetic polyneuropathy. Conclusion. It was established that early administration of alpha­lipoic acid in patients with type II diabetes mellitus and diabetic polyneuropathy leads to improvement of functional heart parameters, and reduces the incidence of rhythm disturbances. Improvement of lipid and carbohydrate metabolism was also noted, which may also have a positive effect on the course and consequences of myocardial infarction in these patients.

Key words: alpha­lipoic acid, myocardial infarction, type II diabetes mellitus, diabetic polyneuropathy.

For reference: Yanovsky KG. The effects of alpha­lipoic acid on the incidence of complications and consequences of myocardial infarction in patients with type II diabetes mellitus and diabetic polyneuropathy. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 42­47. DOI: 10.20969/VSKM.2021.14(4).42­47.

References

  1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn. Brussels, Belgium:International Diabetes Federation, 2019. http://www.diabetesatlas.org

  2. Hajar R. Risk Factors for Coronary Artery Disease: Historical Perspectives. Heart Views. 2017; 18 (3): 109­ 114.

  3. Dedov II, Mel’nichenko GA, Fadeev VF. Endokrinologiya [Endocrinology]. Moskva: GEOTAR­Media [Moscow: GEOTAR­Media]. 2007; 432 p.

  4. Gao L, Mann GE. Vascular NAD(P)H oxidase activation in diabetes: a double­edged sword in redox signalling. Cardiovasc Res. 2009; 82 (1): 9­20.

  5. Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, Krumholz HM. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation. 2005; 111 (23): 3078­3086.

  6. Steinberg HO, Paradisi G, Hook G, Crowder K, Cronin J, Baron AD. Free fatty acid elevation impairs insulin­ mediated vasodilation and nitric oxide production. Diabetes. 2000; 49 (7): 1231­1238.

  7. Morris G, Puri BK, Olive L, Carvalho A, Berk M, Walder K, Gustad LT, Maes M. Endothelial dysfunction in neuroprogressive disorders­causes and suggested treatments. BMC Med. 2020; 18 (1): 305.

  8. Mohort TV. Al’fa­lipoevaya kislota: polifaktornoe vliyanie i obosnovanie vozmozhnostej ispol’zovaniya pri saharnom diabete [Alpha­lipoic acid: polyfactory influence and justi cation of the possibilities of use in diabetes mellitus]. Medicinskie novosti [Medical News]. 2011; 3: 67­71.

  9. Koçak G, Aktan F, Canbolat O, Ozoğul C, Elbeğ S, Yildizoglu­Ari N, Karasu C; ADIC Study Group­Antioxidants in Diabetes­Induced Complications. Alpha­lipoic acid treatment ameliorates metabolic parameters, blood pressure, vascular reactivity and morphology of vessels already damaged by streptozotocin­diabetes. Diabetes Nutr Metab. 2000; 13 (6): 308­318.

  10. Stanković MN, Mladenović D, Ninković M, Ethuričić I, Sobajić S, Jorgačević B, de Luka S, Vukicevic RJ, Radosavljević TS. The effects of α­lipoic acid on liveroxidative stress and free fatty acid composition inmethionine­choline de cient diet­induced NAFLD. J Med Food. 2014; 17 (2): 254­261.

  11. Sergienko VA. Vliyanie benfotiamina na sostoyanie insulinovoj rezistentnosti, soderzhanie nekotoryh pro i protivospalitel’nyh faktorov pri saharnom diabete i kardial’noj avtonomnoj nejropatii [In uence of benfotiamine on the state of insulin resistance, the content of some pro­ and anti­in ammatory factors in diabetes mellitus and cardiac autonomic neuropathy]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2019; 4: 78­82.

  12. Dhumad MM, Hamdan FB, Khudhair MS. Correlation of staging and risk factors with cardiovascular autonomic neuropathy in patients with type II diabetes mellitus. Sci Rep. 2021; 11: 3576.

  13. Brownrigg JR, de Lusignan S, McGovern A, Hughes C, Thompson MM, Ray KK, Hinchliffe RJ. Peripheral neuropathy and the risk of cardiovascular events in type 2 diabetes mellitus. Heart. 2014; 100 (23): 1837­1843.

  14. Uddin F, Ali B, Junaid N. Prevalence Of Diabetic Complications In Newly Diagnosed Type 2 Diabetes Patients In Pakistan: Findings From National Registry. J Ayub Med Coll Abbottabad. 2018; 30 (Suppl 1) (4): 652­658.

  15. Gill HK, Yadav SB, Ramesh V, Bhatia E. A prospectivestudy of prevalence and association of peripheralneuropathy in Indian patients with newly diagnosed type 2 diabetes mellitus. J Postgrad Med. 2014; 60 (3): 270­275.

  16. Zoppini G, Cacciatori V, Raimondo D, Gemma M, Trombetta M, Dauriz M, Brangani C, Pichiri I, Negri C, Stoico V, Bergamini C, Targher G, Santi L, Thomaseth K, Bellavere F, Bonadonna RC, Bonora E. Prevalence of Cardiovascular Autonomic Neuropathy in a Cohort of Patients With Newly Diagnosed Type 2 Diabetes: The Verona Newly Diagnosed Type 2 Diabetes Study (VNDS). Diabetes Care. 2015; 38 (8): 1487­1493.

  17. Pop­Busui R, Evans GW, Gerstein HC, Fonseca V, Fleg JL, Hoogwerf BJ, Genuth S, Grimm RH, Corson MA, Prineas R; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010; 33 (7): 1578­1584.

  18. Kanorskij SG. Sovremennaya farmakoterapiya brillyacii predserdij [Modern pharmacotherapy of atrial brillation]. Rossijskij kardiologicheskij zhurnal [Russian Journal of Cardiology]. 2017; 7: 171­177.

  19. Oh SK, Yun KH, Yoo NJ, Kim NH, Kim MS, Park BR, Jeong JW. Cardioprotective effects of alpha­lipoic Acid on myocardial reperfusion injury: suppression of reactive oxygen species generation and activation of mitogen­ activated protein kinase. Korean Circ J. 2009; 39 (9): 359­366.

  20. DengC,SunZ,TongG,YiW,MaL,ZhaoB,ChengL, Zhang J, Cao F, Yi D. α­Lipoic acid reduces infarct size and preserves cardiac function in rat myocardial ischemia/ reperfusion injury through activation of PI3K/Akt/Nrf2 pathway. PLoS One. 2013; 8 (3): e58371. DOI: 10.1371/ journal.pone.0058371

  21. Dudek M, Knutelska J, Bednarski M, Nowiński L, Zygmunt M, Bilska­Wilkosz A, Iciek M, Otto M, Żytka I, Sapa J, Włodek L, Filipek B. Alpha lipoic acid protects the heart against myocardial post ischemia­reperfusion arrhythmias via KATP channel activation in isolated rat hearts. Pharmacol Rep. 2014; 66 (3): 499­504.

  22. Shen X, Yang Q, Jin P, Li X. Alpha­lipoic acid enhances DMSO­induced cardiomyogenic differentiation of P19 cells. Acta Biochim Biophys Sin (Shanghai). 2014; 46 (9): 766­773.

 

REVIEWS

UDC 616-002.582-084.47:578.834.1(048.8)

DOI: 10.20969/VSKM.2021.14(4).48-57

PDF download SARCOIDOSIS. NEW COVID-19 INFECTION AND VACCINATION ISSUES

VIZEL ALEXANDER A., ORCID ID: 0000-0001-5028-5276; SPIN-code: 5918-5465; Author ID: 195 447; D. Med. Sci., professor, the Head of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(987)296-25-99, e-mail: lordara@inbox.ru

VIZEL IRINA YU., ORCID ID: 0000-0002-8855-8177; SPIN-code: 6000-3813, Author ID: 246 946; D. Med. Sci., professor of Russian Academy of Natural History; associate professor of the Department of phthisiopulmonology of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49; Researcher of Central Research Tuberculosis Institute, Russia, 107564, Moscow, Yauzskaya alley, 2, tel. +7(917)903-91-13, e-mail: tatpulmo@mail.ru

KOSTINOV MIKHAIL P., ORCID ID: 0000-0002-1382-9403; D. Med. Sci., professor, the Head of the Laboratory for vaccine prevention and immunotherapy of allergic diseases of Research institution of vaccines and serums named after Mechnikov, Russia, 105064, Moscow, Maliy Kazenniy lane, 5a; the Head of the Department of epidemiology and modern vaccination technologies of Institute of professional education of I.M. Sechenov First Moscow State Medical University (Sechenov University), Russia, 119991, Moscow, Trubetskaya str., 8, bld. 2, tel. +7(963)782-35-23, e-mail: monolit.96@mail.ru

AMIROV NAIL B., ORCID ID: 0000-0003-0009-9103; SCOPUS Author ID: 7005357664; D. Med. Sci., Academician of RAE, professor of the Department of outpatient therapy and general medical practice of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(905)313-01-11, e-mail: namirov@mail.ru

Abstract. Aim. The aim of the study was to analyze the available publications devoted to the problem of the combination of the new infection COVID­19 and sarcoidosis, and the issues of vaccination in sarcoidosis. The urgency of the problem is dictated by the need to prevent infections in such granulomatosis as well as by the growing worldwide experience of vaccination against COVID­19. Material and methods. An analytical review of 50 publications in the scienti c medical literature was performed. Results and discussion. A review of publications has shown that there is already an accumulation of data on the vaccination of sarcoidosis patients against other manageable infections. We did not come across any papers indicating that vaccinating sarcoidosis patients is dangerous. It remains intriguing to consider any antigenic factors as triggers of sarcoidosis in genetically predisposed individuals. But even from this point of view, an antigenically complete pathogen can play both the role of a trigger and the development of infection in a sarcoidosis patient with drug immunosuppression than a vaccine strain. Regarding vaccination in general and against COVID­19 in particular in advanced sarcoidosis is the statement that the patient should be vaccinated before the start of immunomodulating therapy. Conclusion. From the point of evidence­based medicine, the question of the safety and ef cacy of vaccinating patients with sarcoidosis remains open. The current transnational position is based on the extrapolation of the experience with other vaccines for sarcoidosis and the use of COVID­19 vaccines for other diseases. Understanding COVID­19 as a severe life­threatening disease makes vaccination justi ed, the key position being to assess potential risks, to correct immunosuppressive therapy and, if possible, to vaccinate before the use of hormones and immunosuppressants.

Key words: sarcoidosis, COVID­19, vaccination, infections.

For reference: Vizel AA, Vizel IYu, Kostinov MP, Amirov NB. Sarcoidosis. New COVID­19 infection and vaccination issues. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 48­57. DOI: 10.20969/VSKM.2021.14(4).48­57.

References

  1. Chuchalin AG, Vizel’ AA, Il’kovich MM, Avdeev SN, Ami­ rov NB, Baranova OP, Borisov SE, Vizel’ IYu, Lovachyova OV, Ovsyannikov NV, Petrov DV, Romanov VV, Samso­ nova MV, Solov’eva IP, Solov’eva IP, Stepanyan IE, Tyurin IE, Chernyaev AL, Shmelyov EI, Shmelyova NM. Diagnostika i lechenie sarkoidoza: rezyume federal’nyh soglasitel’nyh klinicheskih rekomendacii; Chast’ 1: Klassifikaciya, etiopatogenez, klinika [Diagnosis and treatment of sarcoidosis: summary of federal consensus clinical guidelines; Part 1: Classi cation, etiopathogenesis, clinic]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary clinical medicine]. 2014 7 (4): 62­70.
  2. Aveyard P, Gao M, Lindson N, Hartmann­Boyce J, Watkinson P, Young D, Coupland CAC, Tan PS, Clift AK, Harrison D, Gould DW, Pavord ID, Hippisley­ Cox J. Association between pre­existing respiratory disease and its treatment, and severe COVID­19: a population cohort study. Lancet Respir Med. 2021 Apr 1: S2213­2600(21)00095­3. DOI: 10.1016/S2213­2600(21)00095­3.
  3. Vizel’ IYu, Vizel’ AA. Rol’ infekcii v patogeneze sarkoidoza [The role of infection in the pathogenesis of sarcoidosis]. Prakticheskaya medicina [Practical medicine]. 2010; 1 (40): 14­17.
  4. Syed H, Ascoli C, Linssen CF, Vagts C, Iden T, Syed A, Kron J, Polly K, Perkins D, Finn PW, Novak R, Drent M, Baughman R, Sweiss NJ. Infection prevention in sarcoidosis: proposal for vaccination and prophylactic therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37 (2): 87­98. DOI: 10.36141/svdld.v37i2.9599.
  5. Garmash YuYu, Borisov SE. Obostrenie latentnoj tuberkuleznoj infekcii u pacientov s sarkoidozom,podvergayushchihsya immunosupressivnoj terapiiglyukokortikosteroidami [Exacerbation of latent tubercu­ losis infection in patients with sarcoidosis undergoing immunosuppressive therapy with glucocorticosteroids]. Tuberkulez i social’no­znachimye zabolevaniya [Tuber­ culosis and socially signi cant diseases]. 2016; 3: 71­73.
  6. Albrecht P, Antczak A, Hryniewicz W, Skoczyńska A, Radzikowski A, Kedziora­Kornatowska K, Bernatowska E, Stompór T, Grodzicki T, Gyrczuk E, Imiela J, Jedrzej­ czak W, Windak A. Recommendations for prevention of community­acquired pneumonia with bacteremia as theleading form of invasive pneumococcal infections in thepopulation of people over 50 years of age and risk groups above 19 years of age. Pol Merkur Lekarski. 2014; 36 (212): 79­87.
  7. Vizel’ AA, Bulashova OV, Amirov NB, Dmitriev EG, Kazakov IM, Islamova LV, Guryleva ME, Nasretdinova GR. Integral’naya model’ diagnostiki i nablyudeniya bol’nyh sarkoidozom v sovremennyh usloviyah [An integral model of diagnostics and observation of patients with sarcoidosis in modern conditions]. Pul’monologiya [Pulmonology]. 2003; 3: 74­79.
  8. Vizel’ IYu, Vizel’ AA. Harakteristika registra bol’nyh sarkoidozom v Respublike Tatarstan [Characteristics of the register of patients with sarcoidosis in the Republic of Tatarstan]. Vestnik sovremennoj klinicheskoj mediciny [Bulletin of contemporary clinical medicine]. 2015; 8 (5): 18­26.
  9. Ungprasert P, Crowson CS, Matteson EL. Sarcoidosis Increases Risk of Hospitalized Infection. A Population­ based Study, 1976­2013. Ann Am Thorac Soc. 2017; 14 (5): 676­681. DOI: 10.1513/AnnalsATS.201610­750OC.
  10. Rossides M, Kullberg S, Di Giuseppe D, Eklund A, Grunewald J, Askling J, Arkema EV. Infection risk in sarcoidosis patients treated with methotrexate compared to azathioprine: A retrospective ‘target trial’ emulated with Swedish real­world data. Respirology. 2021 May; 26 (5): 452­460. DOI: 10.1111/resp.14001.
  11. Syed H, Ascoli C, Linssen CF, Vagts C, Iden T, Syed A, Kron J, Polly K, Perkins D, Finn PW, Novak R, Drent M, Baughman R, Sweiss NJ. Infection prevention in sarcoi­ dosis: proposal for vaccination and prophylactic therapy. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37 (2): 87­98. DOI: 10.36141/svdld.v37i2.9599.
  12. Krause PR, Fleming TR, Longini IM, Peto R, Briand S, Heymann DL, Beral V, Snape MD, Rees H, Ropero AM, Balicer RD, Cramer JP, Muñoz­Fontela C, Gruber M, Gaspar R, Singh JA, Subbarao K, Van Kerkhove MD, Swaminathan S, Ryan MJ, Henao­Restrepo AM. SARS­ CoV­2 Variants and Vaccines. N Engl J Med. 2021 Jul 8; 385 (2): 179­186. DOI: 10.1056/NEJMSR2105280.
  13. Mirsaeidi M, Ebrahimi G, Allen MB, Aliberti S. Pneumococcal vaccine and patients with pulmonary diseases. Am J Med. 2014; 127 (9): 886. DOI: 10.1016/j.amjmed.2014.05.010.
  14. Mirsaeidi M, Schraufnagel DE. Pneumococcal vaccines:understanding centers for disease control and prevention recommendations. Ann Am Thorac Soc. 2014; 11 (6): 980–985.
  15. Papp K, Haraoui B, Kumar D, et al. Vaccination Guidelines for Patients With immune­mediated disorders on immunosuppressive therapies. J Cutan Med Surg. 2019; 23 (1): 50–74.
  16. Mert A, Bilir M, Ozaras R, Tabak F, Karayel T, Senturk H. Results of hepatitis B vaccination in sarcoidosis. Respiration. 2000; 67 (5): 543­545. DOI: 10.1159/000067471.
  17. Seyhan EC, Günlüoğlu G, Altin S, Cetinkaya E, Sökücü S, Uzun H, Düger M. Results of tetanus vaccination in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2012; 29 (1): 3­10.
  18. Centers for Disease Control and Prevention. Recommen­ ded Adult Immunization Schedule, Unites States. 2020. https://www.cdc.gov/vaccines/schedules/downloads/adult/ adult­combined­schedule.pdf
  19. Tavana S, Argani H, Gholamin S, Razavi SM, Keshtkar­ Jahromi M, Talebian AS, Moghaddam KG, Sepehri Z, Azad TM, Keshtkar­Jahromi M. In uenza vaccination in patients with pulmonary sarcoidosis: ef cacy and safety. In uenza Other Respir Viruses. 2012; 6 (2): 136­141. DOI: 10.1111/j.1750­2659.2011.00290.x
  20. Homenko AG, Erohin VV, Filippov VP, et al. Sarkoidoz kak sistemnyj granulematoz [Sarcoidosis as a systemic granulomatosis]. Moskva: Medicina [Moscow: Medicine]. 1999; 39 p.
  21. Agrawal R, Kee AR, Ang L, Tun Hang Y, Gupta V, Kon OM, Mitchell D, Zierhut M, Pavesio C. Tuberculosis or sarcoidosis: Opposite ends of the same disease spectrum? Tuberculosis (Edinb). 2016; 98: 21­26. DOI: 10.1016/j. tube.2016.01.003.
  22. Dubaniewicz A, Kalinowski L, Dudziak M, Kalinowska A, Singh M. Peroxynitrite in sarcoidosis: relation to Mycobacterium stationary hase. Adv Exp Med Biol. 2015; 866: 41­49. DOI: 10.1007/5584_2015_139.
  23. Greally JF, Manning D, McNicholl B. Sarcoidosis following BCG vaccination in a lymphopaenic boy. Sarcoidosis. 1989; 6 (2): 156­157.
  24. Osborne GE, Mallon E, Mayou SC. Juvenile sarcoidosis after BCG vaccination. J Am Acad Dermatol. 2003; 48 (5 Suppl): 99­102. DOI: 10.1067/mjd.2003.158.
  25. Bellet JS, Prose NS. Skin complications of Bacillus Calmette­Guérin immunization. Curr Opin Infect Dis. 2005; 18 (2): 97­100.
  26. Berdel W, Berdel WE. Treatment of sarcoidosis by old tuberculin, blood and BCG I Results. Z Erkr Atmungsorgane. 1979; 153 (2): 189­193.
  27. Berdel WE, Berdel W. Treatment of sarcoidosis by old tuberculin, blood and BCG. II. Case reports. Z Erkr Atmungsorgane. 1979; 153 (2): 194­199.
  28. Heydari­Kamjani M, Vante I, Uppal P, Demory Beckler M, Kesselman MM. Uveitis sarcoidosis presumably initiated after administration of Shingrix Vaccine. Cureus. 2019; 11 (6): e4920. DOI: 10.7759/cureus.4920.
  29. Uslu U, Erdmann M, Schliep S, Dörrie J, Schaft N, Schuler G, Schuler­Thurner B. Sarcoidosis under dendritic cell vaccination immunotherapy in long­term responding patients with metastatic melanoma. Anticancer Res. 2017; 37 (6): 3243­3248.
  30. Psaltis NM, Gardner RG, Denton WJ. Systemic sarcoidosis and red dye granulomatous tattoo in ammation after influenza vaccination: a case report and review of literature. Ocul Immunol In amm. 2014; 22 (4): 314­321. DOI: 10.3109/09273948.2014.891041.
  31. Williams GS, Evans S, Yeo D, Al­bermani A. Retinal artery vasculitis secondary to administration of in uenza vaccine. BMJ Case Rep. 2015: bcr2015211971. DOI: 10.1136/ bcr­2015­211971.
  32. Bauckneht M, Aloè T, Tagliabue E, Cittadini G, Gua­ dagno A, Morbelli S, Barisione E. Beyond Covid­19 vaccination­associated pitfalls on [18F] Fluorodeoxyglucose (FDG) PET: a case of a concomitant sarcoidosis. Eur J Nucl Med Mol Imaging. 2021 Jul; 48 (8): 2661­2662. DOI: 10.1007/s00259­021­05360­w.
  33. Baughman RP, Lower EE, Buchanan M, Rottoli P, Drent M, Sellares J, Terwiel M, Elfferich M, Francesqui J, Barriuso Cabrerizo MR, Sweiss N, Martone F, Al­ Hakim T, Judson MA. Risk and outcome of COVID­19 infection in sarcoidosis patients: results of a self­reporting questionnaire. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37 (4): e2020009. DOI: 10.36141/svdld.v37i4.10726.

  1. ZhouF,YuT,DuR,FanG,LiuY,LiuZ,etal.Clinical course and risk factors for mortality of adult inpatients with COVID­19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054–1062. DOI: 10.1016/ S0140­6736(20)30566­3.

  2. Sweiss NJ, Korsten P, Syed HJ, Syed A, Baughman RP, Yee AMF, Culver DA, Sosenko T, Azuma A, Bonella F, Costabel U, Drake WP, Drent M, Lower EE, Israel­Biet D, Mostard RLM, Nunes H, Rottoli P, Spagnolo P, Wells AU, Wuyts WA, Judson MA. When the game changes:guidance to adjust sarcoidosis management during thecoronavirus disease 2019 Pandemic. Chest. 2020; 158 (3): 892­895. DOI: 10.1016/j.chest.2020.04.033.

  3. Morgenthau AS, Levin MA, Freeman R, Reich DL, Klang E.Moderate or severe impairment in pulmonary function isassociated with mortality in sarcoidosis patients infected with SARS­CoV­2. Lung. 2020; 198 (5): 771­775. DOI: 10.1007/s00408­020­00392­9.

  4. Györ AH, Kopp M, May M, Vetter M, Uder M, Kremer AE, Schett G, Harrer T, Distler JHW. Glucocorticoid­induced relapse of COVID­19 in a patient with sarcoidosis. Ann Rheum Dis. 2020 Jun 30; annrheumdis­2020­218258. doi: 10.1136/annrheumdis­2020­218258.

  5. Kuklina GM, Makar’yanc NN. Opisanie techeniya infekcii COVID­19 u pacienta s mnozhestvennoj komorbidnoj patologiej: volosatokletochnym lejkozom, hronicheskoj formoj generalizovannogo sarkoidoza, trombozom glu­ bokih ven nizhnih konechnostej; Klinicheskij sluchaj [Description of the course of COVID­19 infection in a patient with multiple comorbid pathology: hairy cell leukemia, chronic generalized sarcoidosis, deep vein thrombosis of the lower extremities; Clinical case]. Consilium Medicum. 2021; 23 (3): 292­295. DOI 10.26442/20751753.2021.3.200815

  6. Brito­Zerón P, Gracia­Tello B, Robles A, Alguacil A, Bonet M, De­Escalante B, Noblejas­Mosso A, Gómez­de­ la­Torre R, Akasbi M, Pérez­de­Lis M, Pérez­Alvarez R, Ramos­Casals M, On Behalf Of The SarcoGEAS­Semi Registry. Characterization and Outcomes of SARS­CoV­2 infection in patients with sarcoidosis. Viruses. 2021; 13 (6): 1000. DOI: 10.3390/v13061000.

  7. Lebedeva MV, Beketov VD, Chebotareva NV. Laborato­ rnaya diagnostika v ocenke techeniya generalizovannogo sarkoidoza u bol’nyh, perenesshih novuyu koronavirus­ nuyu infekciyu [Laboratory diagnostics in assessing the course of generalized sarcoidosis in patients who have undergone a new coronavirus infection]. Klinicheskaya laboratornaya diagnostika [Clinical laboratory diagnostics]. 2021; 66 (S4): 36.

41. Ramdani H, Benelhosni K, Moatassim Billah N, Nassar I. COVID­19 pneumonia in a patient with sarcoidosis: A case report. Clin Case Rep. 2020; 9 (2): 910­913. DOI: 10.1002/ccr3.3684.

42. Kiani A, Razavi F, Bandegani N, Farahani M, Abedini A. Investigation of sarcoidosis patients during COVID­19 pandemic. Sarcoidosis Vasc Diffuse Lung Dis. 2020; 37 (4): e2020015. DOI: 10.36141/svdld.v37i4.9588

43. Polat Ekinci A, Büyükbabani N, Meşe S, Pehlivan G, Okumuş NG, Ağaç dan A, Özkaya E. COVID­19­triggered sarcoidal granulomas mimicking scar sarcoidosis. J Eur Acad Dermatol Venereol. 2021 Aug; 35 (8): e477­e480. DOI: 10.1111/jdv.17286.

44. Southern BD. Patients with interstitial lung disease and pulmonary sarcoidosis are at high risk for severe illness related to COVID­19. Cleve Clin J Med. 2020; https://www. ccjm.org/content/early/2020/06/16/ccjm.87a.ccc026DOI: 10.3949/ccjm.87a.ccc026.

45. Ozbalci D. A tale of two diseases: Sarcoidosis, COVID­19 and new therapeutic options with dual RAS inhibition and tetanus­diphtheria vaccine. Med Hypotheses. 2021; 152: 110619. DOI: 10.1016/j.mehy.2021.110619.

46. Calender A, Israel­Biet D, Valeyre D, Pacheco Y. Modeling potential autophagy pathways in COVID­19 and sarcoidosis. Trends Immunol. 2020; 41 (10): 856­859. DOI: 10.1016/j.it.2020.08.001.

47. Prevention CfDCa. Interim Clinical Considerations for Use of mRNA COVID­19 Vaccines Currently Authorized in the United States. 2020. Available from: https://www.cdc.gov/ vaccines/covid­19/info­by­product/clinic

48. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR, et al. American College of Rheu­ matology Guidance for COVID­19 vaccination in patients with rheumatic and musculoskeletal diseases – version 1. Arthritis Rheumatol. 2021; 73 (7): 1093­1107. DOI: 10.1002/art.41734.

49. Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, et al. AntiSARS­CoV­2 antibody responses are attenuated in patients with IBD treated with in iximab. Gut. 2021; 70: 865–875. DOI: 10.1136/gutjnl­2021­324388.

50. Manansala M, Chopra A, Baughman RP, Novak R, Lower EE, Culver DA, Korsten P, Drake WP, Judson MA, Sweiss N. COVID­19 and Sarcoidosis, Readiness for Vaccination: Challenges and Opportunities. Front Med (Lausanne). 2021; 8: 672028. DOI: 10.3389/ fmed.2021.672028.

 

UDC 616.379-008.64-06:578.834.1

DOI: 10.20969/VSKM.2021.14(4).58-66

PDF download DIABETES MELLITUS AND COVID-19. FEATURES OF THE MUTUAL INFLUENCE OF THE TWO PANDEMICS

KOVALENKO JULIYA S., ORCID ID: 0000-0002-7236-7341; С. Med. Sci., assistant of professor of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(952)813-17-96, e-mail: julendo@mail.ru

IVANOVA LIUDMILA A., ORCID ID: 0000-0001-5302-3802; D. Med. Sci., professor, the Head of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(988)242-13-90, e-mail: endocrinkgmu@mail.ru

KOROL’ INNA V., ORCID ID: 0000-0002-3909-9007; C. Med. Sci., associate professor of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(918)414-44-19, e-mail: innakorol1@mail.ru

BIZHEVA TAMILA V., ORCID ID: 0000-0002-3098-8350; second year clinical resident of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(964)937-71-13, e-mail: tamila.bechmukova@mail.ru

Abstract. Background. The COVID­19 pandemic that emerged in China in late 2019 continues to be a global public health problem. The growing incidence of diabetes mellitus makes it necessary to assess the mutual impact of these two diseases on the patient prognosis. Aim. The aim of the study was to review the current information about the effect of SARS­CoV­2 virus on the course of diabetes mellitus and mortality, to consider the probability of developing newly diagnosed diabetes mellitus in patients who underwent COVID­19, and to analyze the possibilities of hypoglycemic therapy in the treatment of COVID­19 diabetic disease. Material and methods. Literature sources were searched in the PubMed database, using the keywords: COVID­19, SARS­CoV­2, and diabetes mellitus. The analysis included literature reviews, meta­analyses, systematic reviews, and clinical trials. Results and discussion. After reviewing about 9,000 sources of literature, 295 of the most relevant publications were analyzed, 60 of which were included in this paper. Insuf ciently controlled diabetes mellitus appears to be independently associated with COVID­19 severity and high risk of death. Patients with severe COVID­19 in the background of diabetes mellitus are more susceptible to the damaging effects of the cytokine storm. Against the background of SARS­CoV­2 infection joining diabetes mellitus, decompensation of the disease with hyperglycemia occurs, which is dif cult to correct even with insulin therapy. SARS­CoV­2 virus has the ability to bind to angiotensin­converting enzyme type 2 receptors that are expressed in β­cells, which can lead to rapid metabolic deterioration with the development of diabetic ketoacidosis or hyperglycemic hyperosmolar syndrome. There is a hypothesis of a potential link between SARS­CoV­2 infection and the development of newly diagnosed diabetes through a direct effect of the virus on pancreatic β­cells. Certain blood glucose­lowering drugs can be continued when infected with SARS­CoV­2 with a positive effect. Conclusions. More research is neededto determine the role of SARS­CoV­2 virus in the development of acute complications and manifestation of diabetes mellitus. Possibilities of modern hypoglycemic therapy of diabetes in COVID­19 are generally evaluated positively and require further study.

Key words: COVID­19, SARS­CoV­2, diabetes mellitus, hyperglycemia, antihyperglycemic agents.

For reference: Kovalenko JuS, Ivanova LA, Korol’ IV, Bizheva NV. Diabetes mellitus and COVID­19. Features of the mutual effects of the two pandemics. The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 58­66.DOI: 10.20969/VSKM.2021.14(4).58­66.

References

  1. McGuire J, Thomson A, Kennedy PG. The Biomechanics of Diabetic Foot Amputation. Wounds. 2021; WNDS20210414­2.

  2. Chen N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet Infectious Diseases. 2020; 395: 507­513.

  3. Walls AC, et al. Structure, function, and antigenicity of the SARS­CoV­2 spike glycoprotein. Cell. 2020; 181: 281­292.

  4. Zhang H, Penninger, JM, Li Y, Zhong N, Slutsky AS. Angiotensin­converting enzyme 2 (ACE 2) as a SARS­ CoV­2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020; 46: 586­590.

  5. Huang C, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet Infectious Diseases. 2020; 395: 497­506.

  6. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID­19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020; 323: 1239­1242.

7. Verity R, et al. Estimates of the severity of coronavirus disease 2019: a model­based analysis. The Lancet Infectious Diseases. 2020; 20 (6): 669­677.

8. Salje H, et al. Estimating the burden of SARS­CoV­2 in France. Science. 2020; 369: 208­211.

9. Fignani D, Licata G, Brusco N, et al. SARS­CoV­2 receptor Angiotensin I­Converting Enzyme type 2 (ACE 2) is expressed in human pancreatic β­cells and in the human pancreas microvasculature. BioRxiv. 2020; doi: https://doi. org/10.1101/2020.07.23.208041

10. Zhu L, She ZG, Cheng X, Qin JJ, Zhang XJ, Cai J, Lei F, Wang H, Xie J, Wang W, et al. Association of Blood Glucose Control and Outcomes in Patients with COVID­19 and Pre­existing Type 2 Diabetes. Cell Metabolism. 2020; 31 (6): 1068­1077.

11. Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID­19­related mortality in England: a whole­population study. The Lancet Diabetes & Endocrinology. 2020; 8 (10): 813­822.

12. Holman N, et al. Risk factors for COVID­19­related mortality in people with type 1 and type 2 diabetes in England: a population­based cohort study. The Lancet Diabetes & Endocrinology. 2020; 8 (10): 823­833.

13. Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID­19 and diabetes: the CORONADO study. Diabetologia. 2020; 63 (8): 1500­1515.

14. Holman N, Knighton P, Kar P, et al. Type 1 and type 2 diabetes and COVID­19 related mortality in England: a cohort study in people with diabetes. HNS England. 2020; https://www.england.nhs.uk/wp­content/ uploads/2020/05/Valabhji­COVID­19­and­Diabetes­Paper­ 2­Full­Manuscript.pdf

15. Sardu C, D’Onofrio N, Balestrieri ML, et al. Outcomes in patients with hyperglycemia affected by Covid­19: can we do more on glycemic control. Diabetes Care. 2020; 43: 1408­1415.

16. Ebekozien OA, Noor N, Gallagher MP, Alonso GT. Type 1 diabetes and COVID­19: preliminary ndings from a multicenter surveillance study in the US. Diabetes Care. 2020; 43 (8): 83­85.

17. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID­19. Diabetes Metabolism Research and Reviews. 2020; 36 (7): 3319.

18. Targher G, Mantovani A, Wang XB, et al. Patients with diabetes are at higher risk for severe illness from COVID­19. Diabetes Metabolism. 2020; 46 (4): 335­337.

19. Wang S, et al. Fasting blood glucose at admission is an independent predictor for 28­day mortality in patients with COVID­19 without previous diagnosis of diabetes: a multi­centre retrospective study. Diabetologia. 2020; 63 (3): 2102­2111.

20. Bode B, Garrett V, Messler J, et al. Glycemic Characteris­ tics and Clinical Outcomes of COVID­19 Patients Hospitalized in the United States. Journal of Diabetes Science and Technology. 2020; 14 (4): 813­821.

21. Riddle MC, Buse JB, Franks PW, et al. COVID­19 in People with Diabetes: Urgently Needed Lessons From Early Reports. Diabetes Care. 2020; 43: 1378.

22. Kanorskij SG. COVID­19 i ozhirenie: chto izvestno ob osobennostyah patogeneza i lecheniya? [COVID­19 and obesity: what is known about the features of pathogenesis and treatment?]. Yuzhno­Rossijskij zhurnal terapevticheskoj praktiki [South Russia Journal of Therapeutic Practices]. 2021; 2 (1): 17­24. DOI: 10.21886/2712­8156­2021­2­1­17­24.

23. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID­19: an overview of the involvement of the chemokine/chemokine­receptor system. Cytokine Growth Factor Reviews. 2020; 53: 25­32.

  1. Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID­19 in people with diabetes: understanding the reasons for worse outcomes. The Lancet Diabetes & Endocrinology. 2020; 8 (9): 782­ 792.

  2. Zeng Z, et al. Longitudinal changes of inflammatory parameters and their correlation with disease severity and outcomes in patients with COVID­19 from Wuhan, China. Critical Care. 2020; 24 (1): 525.

  3. Lim S, Bae JH, Kwon HS, Nauck MA. COVID­19 and diabetes mellitus: from pathophysiology to clinical management. Nature Reviews Endocrinology. 2021; 17 (1): 11­30.

  4. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of Thrombosis and Haemostasis. 2020; 18 (4): 844­847.

  5. Sathish T, Tapp RJ, Cooper ME, Zimmet P. Potential metabolic and in ammatory pathways between COVID­19 and new­onset diabetes. Diabetes Metabolism. 2021; 47 (2): 101204.

  6. Yang JK, Feng Y, Yuan MY, et al. Plasma glucose levelsand diabetes are independent predictors for mortality andmorbidity in patients with SARS. Diabetic Medicine. 2006; 23 (6): 623­628.

  7. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus infected pneumonia in Wuhan, China. JAMA. 2020; 323: 1061.

  8. Wu L, Girgis CM, Cheung, NW. COVID­19 and diabetes: insulin requirements parallel illness severity in critically unwell patients. Clinical Endocrinology. 2020; 93: 390­393.

  9. Gianchandani R, et al. Managing hyperglycemia in the COVID­19 inflammatory storm. Diabetes. 2020; 69: 2048­2053.

  10. Rayman G, Lumb A, Kennon B, et al. Guidance on the management of diabetic ketoacidosis in the exceptional circumstances of the COVID­19 pandemic. Diabetic Medicine. 2020; 37: 1214­1216.

  11. Kim NY, Ha E, Moon JS, Lee Y­HH, Choi EY. Acute hyperglycemic crises with coronavirus disease­19: case reports. Diabetes Metabolism. 2020; 44: 349­353.

  12. Li J, Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID­19 infection may cause ketosis and ketoacidosis. Diabetes, Obesity and Metabolism. 2020; 22 (10): 1935­1941.

  13. Pal R, Banerjee M, Yadav U, Bhattacharjee S. Clinical pro le and outcomes in COVID­19 patients with diabetic ketoacidosis: a systematic review of literature. Diabetes Metabolism. 2020; 14: 1563­1569.

  14. Hollstein T, Schulte DM, Schulz J, et al. Autoantibody­ negative insulin­dependent diabetes mellitus after SARS­ CoV­2 infection: a case report. Nature Metabolism. 2020; 2: 1021­1024.

  15. Filippi CM, von Herrath MG. Viral trigger for type 1 diabetes: pros and cons. Diabetes. 2008; 57: 2863­2871.

  16. Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent­onset type 1 diabetic patients. Proceedings of the National Academy of Sciences. 2007; 104: 5115.

  17. Muller J, Grob R, Conzelmann C, et al. SARS­CoV­2infects and replicates in cells of the human endocrineand exocrine pancreas. Nature Metabolism. 2021; 3: 149­165.

  18. Rubino F, Amiel SA. New­Onset Diabetes in Covid­19. The New England Journal of Medicine. 2020; 383: 789­-790.

  19. Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID­19 patients: A systematic review and meta­analysis. Diabetes Obesity Metabolism. 2021; 23: 870.

43. Potier L, et al. COVID­19 symptoms masking inaugural ketoacidosis of type 1 diabetes. Diabetes Metabolism. 2020; 47 (1): 101162.

44. Marchand L, Pecquet M, Luyton C. Type 1 diabetes onset triggered by COVID­19. Acta Diabetology. 2020; 57 (10): 1265­1266.

45. Smith SM, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID­19. Journal of Medical Virology. 2021; 93 (1): 409­415.

46. Rabbone I, et al. Has COVID­19 delayed the diagnosis and worsened the presentation of type 1 diabetes in children? Diabetes Care. 2020; 43: 2870­2872.

47. Unsworth R, et al. New – onset type 1 diabetes in children during COVID­19: multicenter regional ndings in the U.K. Diabetes Care. 2020; 43: 170­171.

48. Ministerstvo zdravoohraneniya Rossiyskoy Federatsii [Ministry of Health of the Russian Federation]. Vremennye metodicheskie rekomendacii «Pro laktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID­19)» [Temporary guidelines «Prevention, diagnosis and treatment of new coronavirus infection (COVID­19)»]. Moskva [Moscow]. 2021; 11: 225 p.

49. Sharma S, Ray A, Sadasivam B. Metformin in COVID­19: a possible role beyond diabetes. Diabetes Research and Clinical Practice. 2020; 164: 108183.

50. Kim J, Kwak HJ, Cha JY, et al. Metformin suppresses lipopolysaccharide (LPS)­induced in ammatory response in murine macrophages via activating transcription factor­3 (ATF­3) induction. Journal of Biological Chemistry. 2014; 289 (33): 23246­23255.

51. Roussel R, Darmon P, Pichelin M, et al. Use of dipeptidyl peptidase­4 inhibitors and prognosis of COVID­19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study. Diabetes Obesity Metabolism. 2021; 23:1162.

52. Zhou JH, Wu B, Wang WX, et al. No signi cant association between dipeptidyl peptidase­4 inhibitors and adverse outcomes of COVID­19. World Journal of Clinical Cases. 2020; 8: 5576.

53. Athauda D, et al. Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double­blind, placebo­ controlled trial. Lancet. 2017; 390: 1664­1675.

54. Prattichizzo, F. et al. Glucose­lowering therapies in patients with type 2 diabetes and cardiovascular diseases. European Journal of Preventive Cardiology. 2019; 26: 73­80.

55. Bornstein SR, Rubino F, Khunti K, et al. Practicalrecommendations for the management of diabetes inpatients with COVID­19. Lancet Diabetes Endocrinology. 2020; 8(6): 546­550.

56. Cure E, Cure CM. Can dapagli ozin have a protective effect against COVID­19 infection? A hypothesis. Diabetes & Metabolic Syndrome. 2020; 14: 405­406.

57. Kosiborod M, et al. Effects of dapagli ozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID­19: Design and rationale for the DARE­19 study. Diabetes Obesity Metabolism. 2021; 23 (4) :886­896.

58. Hahn K, Ejaz AA, Kanbay M, Lanaspa MA, Johnson RJ. Acute kidney injury from SGLT2 inhibitors: potential mechanisms. Nature Reviews Nephrology. 2016; 12 (12): 711­712.

59. Ciavarella C, Motta I, Valente S, Pasquinelli G. Phar­ macological (or Synthetic) and Nutritional Agonists of PPAR­γ as Candidates for Cytokine Storm Modulation in COVID­19 Disease. Molecules. 2020; 25 (9): 2076.

60. Kernan WN, et al. Pioglitazone after ischemic stroke or transient ischemic attack. The New England Journal of Medicine. 2016; 374: 1321­1331.

 

ORGANIZATION OF HEALTHCARE

UDC 614.2(470.41):616.314-089.28

DOI: 10.20969/VSKM.2021.14(4).67-72

PDF download INCREASING THE MEDICAL AND SOCIAL EFFECTIVENESS OF THE PREFERENTIAL DENTAL PROSTHETICS PROGRAM FOR CERTAIN CATEGORIES OF CITIZENS IN THE REPUBLIC OF TATARSTAN

SHAYMIEVA NAILYA I., ORCID ID: 0000-0001-6881-9790; C. Med. Sci., associate professor, the Head of the Department of prosthetics and general dentistry of Kazan State Medical Academy – the branch of Russian Medical Academy of Postgraduate Education, Russia, 420012, Kazan, Butlerov str., 16, e-mail: nailya.shaymieva@mail.ru

KHASANOV RUSTEM SH., ORCID ID: 0000-0003-4107-8608; Corresponding Member of RAS, D. Med. Sci., professor, the Head of the Department of oncology, radiology and palliative medicine of Kazan State Medical Academy – the branch of Russian Medical Academy of Postgraduate Education, Russia, 420012, Kazan, Butlerov str., 36

OLESOVA VALENTINA N., ORCID ID: 0000-0002-7376-1535; D. Med. Sci., professor, the Head of the Department of dentistry of State Research Center Federal Medical Biophysical Center named after A.I. Burnazyan, Russia, 123098, Moscow, Zhivopisnaya str., 46/8

Abstract. Background. The study is devoted to improving the medical and social effectiveness of the Privileged Dental Prosthetics Program for certain categories of citizens in the Republic of Tatarstan. Aim. The aim of the study was to develop new tactical approaches to implement a targeted program of dental prosthetics for certain groups of the population in the Republic of Tatarstan in the complete absence of teeth aimed at the introduction of modern treatment technologies. Material and methods. We applied a complex method using: method of expert evaluation of the Program of free dental prosthetics in the Republic of Tatarstan, method of organizational modeling for the development of new tactical approaches in the implementation of the Program, method of statistical cost prediction in comparing three approaches to dentures for edentulous mandibles at the expense of the Program. Analysis of aggregate data obtained in the calculation of the comparative economic ef ciency of the traditional method, the use of dental implant quota and the introduction of the number of applications for the fabrication of a complete removable denture in persons over 60 years in the medium­term forecast of 10 years was conducted. Statistical processing was performed in MS Windows software. Results and discussion. At the level of the Ministry of Health of the Republic of Tatarstan, when implementing the additional MHI program of free denture prosthetics for certain categories of citizens, tactical approaches have been introduced, implying a frequency of visits with complete removable prosthetics – once every three years, according to the service life of the prosthesis. Every year since 2015, an order has been issued by the Ministry of Health of the Republic of Tatarstan. Saving funds of the Program for this section of dental prosthetics reaches more than 8,8 million rubles (67%) per year. Rational use of the funds of the compulsory medical insurance program makes it possible to manufacture modern constructions with the use of dental implantation in 200 people a year. Conclusion. The developed tactical approaches of using the funds of the Territorial Program of Compulsory Medical Insurance for free dental prosthetics in the Republic of Tatarstan serve as a reserve for the introduction of modern technologies of treatment with the use of dental implants on edentulous jaws.

Key words: preferential dental prosthetics program, certain groups of people over 60 years old, tactical approaches, complete absence of teeth.

For reference: Shaymieva NI, Khasanov RSh, Olesova VN. Increasing the medical and social effectiveness of the Preferential Dental prosthetics program for Certain Categories of Citizens in the Republic of Tatarstan. The Bulletin ofContemporary Clinical Medicine. 2021; 14 (4): 67­72. DOI: 10.20969/VSKM.2021.14(4).67­72.

References

  1. Leontyev VK. Ob etiologii kariesa zubov [On Etiology of Dental Caries]. Institut stomatologii [The dental institute]. 2019; 1: 34­35.
  2. Roshkovskij EV. Izuchenie nuzhdaemosti v ortopedi­ cheskoj stomatologicheskoj pomoshchi lic pozhilogo i starcheskogo vozrasta, a takzhe dolgozhitelej i osoben­ nosti ee okazaniya v gerontologicheskih stacionarah: avtoreferat dissertacii kandidata medicinskih nauk [Thestudy of the need for orthopedic dental care for elderlyand senile people, as well as long­livers and the features of its provision in gerontological hospitals: abstract for the degree of Candidate of medical sciences]. Moskva [Moscow]. 2008; 26 p.
  3. Ramseier CA, Anerud A, Dulac M, et al. Natural history of periodontitis: Disease progression and tooth loss over 40 years. J Clin Periodontol. 2017; 44 (12): 1182­1191.

  1. Manresa C, Sanz­Miralles EC, Twigg J, Bravo M. Supportive periodontal therapy (SPT) for maintaining the dentition in adults treated for periodontitis. Cochrane Database Syst Rev. 2018; 1: CD009376.

  2. Kuzmina EM, Yanushevich OO, Kuzmina IN, Lapatina AV. Tendencii rasprostranennosti i intensivnosti kariesa zubov sredi naseleniya Rossii za 20­letnij period [Tendency in theprevalence of dental caries among the russian populationover a 20­year period]. Dental Forum. 2020; 3: 2­8.

  3. Baginski AL, Chizhov YuV. Nuzhdaemost’ vzroslogo naseleniya v ortopedicheskoj stomatologicheskoj pomoshchi Evenkijskogo municipal’nogo rajona Krasno­ yarskogo kraya [Need for adult population in orthopedic dental care Evenk municipal district of Krasnoyarsk territory]. Institut Stomatologii [The dental institute]. 2016; 2: 24­25.

  4. Kamieva NA, Kausova GK, Ruzuddinov SR. K voprosunuzhdaemosti v zubnom protezirovanii lic pozhilogovozrasta [Dental prosrhetics need among elderly]. Vestnik Kazahskogo nacional’nogo medicinskogo universiteta [Vestnik KazNMU]. 2018; 4: 41­45.

  5. Kurbanov OR. Opredelenie potrebnosti naseleniya v razlichnyh vidah zubnyh protezov [Evaluation of the population need in various types of dentures]. Vestnik Medicinskogo stomatologicheskogo instituta [Journal of Medical Dental Institute]. 2016; 3: 13­16.

  6. Hoeksema AR, Peters LL, Raghoebar GM, et al. Oral health status and need for oral care of care­dependent indwelling elderly: from admission to death. Clin Oral Investig. 2017; 21 (7): 2189­2196.

  7. Campbell SD, Cooper L, Craddock H, et al. Removable partial dentures: the clinical need for innovation. J Prosthet Dent. 2017; 118 (3): 273­280.

  8. Leous P, Tserekhova TN, Kiselnikova LP. Retrospektivnaya ocenka effektivnosti kompleksnoj pro laktiki kariesa zubov [Retrospective evaluation of the complex program for prevention of dental caries]. Stomatologicheskij zhurnal [Dental magazine]. 2019; 20 (1): 5­11.

  9. Ha zova FA, Mirgazizov RM, Ha zov RG, et al. Povyshe­ nie kachestva okazaniya stomatologicheskoj pomoshchi dlya lic pozhilogo vozrasta s primeneniem individual’nyh konstrukcij protezov izgotovlennyh iz nanostrukturnyh importozameshchayushchih materialov [Improving the quality of dental care for the elderly with the use ofindividual prosthesis designs made of nanostructuredimport­substituting materials]. Kachestvo okazaniya medicinskoj stomatologicheskoj pomoshchi: sposoby dostizheniya, kriterii i metody ocenki: sbornik statej Mezhdunarodnoi nauchno­prakticheskoy konferencii [Quality of medical dental care: methods of achievement, criteria and methods of evaluation: collection of articles of the International Scienti c and Practical Conference]. Kazan [Kazan]. 2016; 3­8.

13. Shaymieva NI. Aktual’nye problemy okazaniya l’gotnogo zuboprotezirovaniya otdel’nym kategoriyam grazhdan v respublike Tatarstan [Actual problems of providingpreferential dental prosthetics to certain categories ofcitizens in the Republic of Tatarstan]. Aktual’nye voprosy stomatologii: sbornik nauchnyh trudov posvyashchyonnyj 120­letiyu osnovatelya kafedry ortopedicheskoj sto­ matologii KGMU professora Isaaka Mihajlovicha Oksmana [Actual issues of dentistry: a collection of scientific papers dedicated to the 120th anniversary of the founder of the Department of Orthopedic Dentistry of KSMU, Professor Isaac Mikhailovich Oxman]. Kazan’: Izdatel’stvo «Otechestvo» [Kazan: Publishing House “Fatherland”]. 2012; 337­341.

14. Nazarenko TM. Pravo invalidov na besplatnoe obes­ pechenie sredstvami reabilitacii (zubnye protezy) i osobennosti ego realizacii [The right of disabled people for free provision of rehabilitation facilities (dentures) and features of its implementation]. Via scientiarum – Doroga znanij [Via scientiarum – The way of science]. 2015; 2: 75­78.

15. Bulgakova AI, Dyumeev RM, Islamova DM, Aznagulov AA. Rezul’taty issledovaniya realizacii celevoj program­ my «Predostavlenie mer social’noj podderzhki po zuboprotezirovaniyu otdel’nym kategoriyam grazhdan v Respublike Bashkortostan» [Results of the targeted program “Social support for providing access to prosthetic dentistry for certain citizen categories of the Republic of Bashkortostan” evaluation]. Kazanskij medicinskij zhurnal [Kazan medical journal]. 2013; 94 (4): 526­528.

16. Olesov EE, Shaymieva NI, Havkina EYu, et al. Srav­ nenie stomatologicheskogo statusa i oshibok pred­shestvuyushchego lecheniya i protezirovaniya u pacientovna besplatnom i platnom priemah [Comparison of dentalstatus and errors of previous treatment and prostheticsin patients on free and paid methods]. Rossijskij stomatologicheskij zhurnal [Russian journal of dentistry]. 2013; 4: 48­50.

17. Shaymieva NI. Aktual’nye problemy protezirovaniya pripolnoj vtorichnoj adentii nizhnej chelyusti u lic starshegovozrasta, pol’zuyushchihsya l’gotami [Actual problems of prosthetics with complete secondary adentia of the lower jaw among older people using state bene ts] Sovremennye aspekty ortopedicheskoj stomatologii: sbornik materialov kafedry ortoped. stomatologii No 1 (k 75­letiyu kafedry) [Modern aspects of orthopedic dentistry: a collection of materials of the orthopedic Department. dentistry No 1 (to the 75th anniversary of the department)]. Kazan: Medicina [Kazan: Medicine]. 2008; 49­53.

 

PRACTICAL EXPERIENCE

UDC 616-441-006.5-076

DOI: 10.20969/VSKM.2021.14(4).73-77

PDF download AN ALGORITHM FOR MORPHOLOGICAL DIAGNOSIS OF NODULAR GROWTHS IN THE THYROID GLAND (clinical experience)

ZIMA DMITRY V., ORCID ID: 0000-0003-4732-0311; surgeon of Clinical medical multidisciplinary center of St. Luke (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7

BEZRUKOV OLEG F., ORCID ID: 0000-0002-0161-8959; D. Med. Sci., the Head of the Department of surgical of clinical medical multidisciplinary center of St. Luke (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7

GOLUBINSKAYA ELENA P., ORCID ID: 0000-0003-3917-924X; D. Med. Sci., leading researcher of Central research laboratory of Medical academy named after S.I. Georgievsky (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7

ZYABLITSKAYA EVGENIA YU., ORCID ID: 0000-0001-8216-4196; D. Med. Sci., leading researcher of Central research laboratory of Medical academy named after S.I. Georgievsky (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7, e-mail: evgu79@mail.ru

MAKALISH TATYANA P., ORCID ID: 0000-0003-1884-2620; C. Biol. Sci., junior researcher of Central research laboratory of Medical academy named after S.I. Georgievsky (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Simferopol, Lenin av., 5/7

MAXIMOVA РOLINA E., ORCID ID: 0000-0001-5920-8664; fourth year student of First medical faculty of the Medical academy named after S.I. Georgievsky (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Lenina av., 5/7

NEPRITIMOVA ELENA A., ORCID ID: 0000-0001-8989-3615; junior researcher of Central research laboratory of Medical academy named after S.I. Georgievsky (structural unit) of V.I. Vernadsky Crimean Federal University, Russia, 295051, Lenin av., 5/7

Abstract. Background. To date, there are two opposing views among surgeons regarding surgical intervention in the early stages of thyroid cancer. Since after the introduction of ne­needle aspiration biopsy with cytological examination of biopsy sample into clinical practice the number of patients with early stages of papillary cancer who undergo surgical interventions has increased. Among all methods of diagnosis of thyroid neoplasms the leading role is currently given to ne­needle aspiration biopsy. Aim. The aim of the study was to demonstrate the results of our clinical experience of applying the algorithm of morphological diagnostics of thyroid nodular masses with regard to regional peculiarities and the proposed adjuvant immunohistochemical method. Material and methods. Thin aspiration biopsy material of the thyroidgland was used to make a cell block, semi­thin sections from which were stained by immunohistochemical methods for the expression of proliferation (Ki67) and apoptosis (Fas) markers. Positive stained cells were assessed and counted under a microscope at 100× magni cation, and the ratio of these values was calculated. Results and discussion.Having analyzed the results of staining for the expression of apoptosis and proliferation markers and compared them with the results of pathomorphological examination of the material from which the clot was obtained, we developed a diagnostic algorithm for veri cation of «doubtful» changes, e.g.: papillary structures, cytoplasmic plasmacytoid, presence of intranuclear furrows, piling of nuclei and their enlargement, immunocytochemical or immunohistochemical reaction with Ki67, and Fas­R markers to determine the malignant potential (Z­index) is being performed. Conclusion. Isolated assessment of immunocytochemical reactions with Fas or Ki67 markers on ne­needle aspiration biopsy material is not diagnostically signi cant. However, it can be used in combination with cytological characteristics of a smear for prognostic assessment of malignant potential of a neoplasm.

Key words: thyroid gland, pathology, cancer, morphological diagnosis, surgery.

For reference: Zima DV, Bezrukov OF, Zyablitskaya EYu, Makalish TP, Maximova PE, Nepritimova EA. An algorithm for morphological diagnosis of nodular growths in the thyroid gland (clinical experience). The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 73­77. DOI: 10.20969/VSKM.2021.14(4).73­77.

References

  1. Feldkamp J, Führer D, Luster M, Musholt TJ, Spitzweg C, Schott M. Fine Needle Aspiration in the Investigation of Thyroid Nodules. Dtsch Arztebl Int. 2016; 113 (20): 353–359. DOI: 10.3238/arztebl.2016.0353.

  2. Gabaidze DI, Ippolitov LI. Spornyevoprosy v diagnostike i hirurgicheskom lechenii pacientov s «follikulyarnoj neoplaziej» shchitovidnoj zhelezy [Controversial issues in the diagnosis and surgical treatment of patients with «follicular neoplasia» of the thyroid gland]. Golova i sheya [Head and neck]. 2019; 2: 70­74. DOI: 10.25792/ HN.2019.7.2.70–74.

  3. Mihajlova MV, Zubarovskij IN, Osipenko SK. Diagnos­ ticheskaya i lechebnaya taktika pri «follikulyarnoj opuholi» shchitovidnoj zhelezy [Diagnostic and therapeutic tactics for «follicular tumor» of the thyroid gland]. Vestnik hirurgii imуni II Grekova [II Grekov Bulletin of surgery]. 2015; 2: 77­80. DOI: 10.24884/0042­4625­2015­174­2­77­80.

  4. Orlinskaya NYu, Hmel’nickaya NM, Fedorov AA, Bede­ rina EL. Kliniko­morfologicheskaya I immunogisto­ himicheskaya harakteristika follikulyarnyh opuholej shchitovidnoj zhelezy [Clinical, morphological andimmunohistochemical characteristics of thyroid folliculartumors]. Medicinskij al’manah [Medical almanac]. 2015; 2 (37): 135­138.

  5. Vargas­Pinto S, Minerva A, Arenas R. Lobectomy Compared to Total Thyroidectomy for Low­Risk Papillary Thyroid Cancer: A Systematic Review. Journal of Surgical Research. 2019; 242: 244­251. DOI: 10.1016/j. jss.2019.04.036.

  6. Ahmed SA, Basha MA, Elsha e SM. 1870P – Thyroid lobectomy versus total thyroidectomy among early­stage papillary thyroid carcinoma patient. Annals of Oncology. 2019; 30: 758. DOI: 10.1093/annonc/mdz267.007.

  7. Rebecca D Chernock. Immunohistochemistry of thyroid gland carcinomas: clinical utility and diagnostic pitfalls. Diagnostic Histopathology. 2016; 22 (5): 184­190. DOI: 10.1016/j.mpdhp.2016.04008

  8. Styazhkina SN, Poryvaeva EL, Klimentov MN, Ledneva AV. Vozmozhnosti immunogistohimicheskogo issledovaniya dlya ocenki proliferativnoj aktivnosti tkani shchitovidnoj zhelezy [Possibilities of immunohistochemical studies to assess the proliferative activity of thyroid tissue]. Sovremennye problem nauki I obrazovaniya [Modern problems of science and education]. 2017; 2: 21.

  9. Kalmin OV, Chairkin II, Kalmin OO. Imunogisto­ himicheskoe issledovanie follikulyarnyh opuholej shchitovidnoj zhelezy [Imunohistochemical study of thyroid follicular tumors]. Izvestiya vysshih uchebnyh zavedenij [Proceedings of higher educational institutions]. 2017; 1 (41): 28­38.

  10. Peter ME, Hadji A, Murmann AE, Brockway S, Putzbach W, Pattanayak A, Ceppi P. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 2015; 22 (5): 885­886. DOI: 10.1038/cdd.2015.3.

  11. Gel’cer BI, Zdor VV, Kotel’nikov VN. Evolyuciya vzglyadovna patogenez autoimmunnyh zabolevanij shchitovidnojzhelezy i perspektivy ih targetnoj terapii [Evolution of viewson the pathogenesis of autoimmune thyroid diseases andthe prospects for their targeted therapy]. Klinicheskaya medicina [Clinical medicine]. 2017; 6: 524­534.

  12. Cruz AC, Ramaswamy M, Ouyang C, Klebanoff CA, Sengupta P, Yamamoto TN, Meylan F, Thomas SK, Richoz N, Eil R, Price S, Casellas R, Rao VK, Lippincott­ Schwartz J, Restifo NP, Siegel RM. Fas/CD95 preventsautoimmunity independently of lipid raft localization andef cient apoptosis induction. Nat Commun. 2016; (7): 13895. DOI: 10.1038/ncomms13895.

  13. Vorob’ev SL. Morfologicheskaya diagnostika zabolevanij shchitovidnoj zhelezy (citologiya dlya patologov, patologiya dlya citologov) [Morphological diagnostics of thyroid diseases (cytology for pathologists, pathology for cytologists]. SPb: Izdatel’sko­poligra cheskaya kompaniya «KOSTA» [SPb: Publishingand printing company «KOSTA»]. 2014; 102 p.

  

UDC 616-039.42-053.2

DOI: 10.20969/VSKM.2021.14(4).78-84

PDF download A CURRENT VIEW OF PFAPA-SYNDROME (MARSHALL SYNDROME) IN CHILDREN (clinical observation)

LUTFULLIN ILDUS YA., ORCID ID: 0000-0002-0224-2746; C. Med. Sci., associate professor of the Department of pediatrics and neonatology named after professor E.M. Lepsky of Kazan State Medical Academy – the branch of Russian Medical Academy of Postgraduate Education, Russia, 420012, Kazan, Butlerov str., 36, tel. +7(904)766-54-28, e-mail: Lutfullin@list.ru

SALUGINA SVETLANA O., ORCID ID: 0000-0003-3689-431X; D. Med. Sci., leading researcher of the Laboratory of pediatric rheumatic of diseases of Research Institute of Rheumatology named after V.A. Nasonova, Moscow, 115522, Kashirskoe highway, 34a, tel. +7(985)761-48-49

DAMINOVA MARIA A., ORCID ID: 0000-0001-6445-0893; C. Med. Sci., associate professor of the Department of pediatrics and neonatology named after professor E.M. Lepsky of Kazan State Medical Academy – the branch of Russian Medical Academy of Postgraduate Education, Russia, 420012, Kazan, Butlerov str., 36, tel. +7(917)262-47-79, e-mail: daminova-maria@yandex.ru

GAZIZOV ILNAZ M., ORCID ID: 0000-0003-3396-8643; SCOPUS ID: 37112160700; C. Med. Sci., associate professor of the Department of human anatomy of Kazan State Medical University, Russia, 420012, Kazan, Butlerov str., 49, tel. +7(904)661-20-01, e-mail: ilnazaziz@mail.ru

Abstract. Background. PFAPA syndrome is the most common cause of recurrent fever in children. Despite the long history of the disease, the etiology and pathogenesis of the disease have not been de nitively established. Aim. Analysis of the scienti c medical literature on PFAPA syndrome (Marshall syndrome) with the presentation of personal clinical observation. Material and methods. An analysis of the medical literature devoted to the problem has been performed. A clinical case of a child with Marshall syndrome is presented. Results and discussion. The nature of the diseaseis associated with cytokine dysfunction and dysregulation of the in ammasome, which allows it to be classi ed as an autoin ammatory syndrome. The diagnosis of the disease is based on clinical and history criteria, the speci city of which has been questioned in recent years; new diagnostic criteria are now proposed. Despite the absence of double­blind randomized clinical trials, there is a wealth of experience with therapeutic approaches to PFAPA syndrome, including the administration of glucocorticoids, colchicine, and tonsillectomy. Our clinical example illustrates the problem of late diagnosis of PFAPA syndrome, the effectiveness of using glucocorticoids to control attacks as rst­line therapy,and the need for different therapeutic approaches and differential diagnosis in complicated cases of monogenicautoin ammatory diseases. Conclusion. PFAPA syndrome is the most prevalent hereditary periodic fever syndrome. The exact epidemiology of the disease has not been studied, but it is assumed that the number of diagnosed cases is signi cantly lower than the actual prevalence of the disease. Attempts to revise the diagnostic criteria of PFAPA syndrome are currently underway. Despite the lack of randomized double­blind clinical trials to date, therapeutic strategies continue to improve.

Key words: PFAPA syndrome, Marshall syndrome, children, periodic febrile syndromes, treatment.

For reference: Lutfullin IYa, Salugina SO, Daminova MA, Gazizov IM. A current view of PFAPA syndrome (Marshall syndrome) in children (clinical observation). The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 78­84.DOI: 10.20969/VSKM.2021.14(4).78­84.

References

1. Marshall GS, Edwards KM, Butler J, Lawton AR. Syndrome of periodic fever, pharyngitis, and aphthous stomatitis. J Pediatr. 1987; 110 (1): 43–46.

2. Sa na AI, Lutfullin IYa, Zakirov KZ, Shapiro VYu. Sluchay trudnoy diagnostiki bol’noy s sindromom Marshalla [A case of dif cult diagnosis of a patient with Marshall syndrome]. Kazanskiy meditsinskiy zhurnal [Kazan Medical Journal]. 2011; 92 (2): 287­289.

3. Kuznetsova SA, Zryachkin NI, Tsareva YuA, et al. PFAPA­sindrom: sovremennaya paradigma i opisaniye klinicheskogo sluchaya [PFAPA­syndrome: modern paradigm and description of a clinical case]. Al’manakh klinicheskoy meditsiny [Almanac of Clinical Medicine]. 2018; 46 (2): 184­193. DOI 10.18786/2072­0505­2018­ 46­2­184­193.

4. Wurster VM, Carlucci JG, Feder HM Jr, Edwards KM. Long­ term follow­up of children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome. J Pediatr. 2011; 159 (6): 958–964.

5. Kozlova AL, Barabanova OV, Kalinina MP, Shcherbi­ na AYu. Autovospalitel’nyye sindromy v pediatrii (obzor literatury i sobstvennyye klinicheskiye nablyudeniya) [Autoin ammatory syndromes in pediatrics (literature review and own clinical observations)]. Doktor Ru [Doctor Ru]. 2015; 10 (111): 38­45.

6. Vanoni F, Theodoropoulou K, Hofer M. PFAPA syndrome: a review on treatment and outcome. Pediatr Rheumatol Online J. 2016; 14 (1): 38.

7. Førsvoll J, Kristoffersen EK, Øymar K. Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome; a population­based study. Acta Paediatr. 2013; 102: 187–192.

8. Cantarini L, Vitale A, Bartolomei B, Galeazzi M, Rigante D. Diagnosis of PFAPA syndrome applied to a cohort of  17 adults with unexplained recurrent fevers. Clin Exp Rheumatol. 2012; 30 (2): 269–271.

9. Federici S, Martini A, Gattorno M. The central role of anti­IL­1 blockade in the treatment of monogenic and multi­factorial autoin ammatory diseases. Front Immunol. 2013; 4: 351.

10. Manthiram K, Nesbitt E, Morgan T, Edwards KM. Family History in Periodic Fever, Aphthous Stomatitis, Pharyngitis, Adenitis (PFAPA) Syndrome. Pediatrics. 2016; 138 (3): e20154572.

11. Perko D, Debeljak M, Toplak N, Avčin T. Clinical features and genetic background of the periodic fever syndrome with aphthous stomatitis, pharyngitis, and adenitis: a single center longitudinal study of 81 patients. Mediators In amm. 2015; 2015: 293417.

12. Dagan E, Gershoni­Baruch R, Khatib I, Mori A, Brik R. MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatol Int. 2010; 30 (5): 633–636.

13. Kolly L, Busso N, Von Scheven­Gete A, Bagnoud N, Moix I, Holzinger D, Simon G, Ives A, Guarda G, So A, Morris MA, Hofer M. Periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome is linked to dysregulated monocyte IL­1β production. J Allergy Clin Immunol. 2013; 131 (6): 1635–1643.

14. Thomas, K. T. Edwards, K. M. Periodic fever syndrome. The Pediatric Infectious Disease Journal. 1999; 18 (1): 68­69.

15. Gattorno M, Caorsi R, Meini A, Cattalini M, Federici S, Zulian F, Cortis E, Calcagno G, Tommasini A, Consolini R, Simonini G, Pelagatti MA, Baldi M, Ceccherini I, Plebani A, Frenkel J, Sormani MP, Martini A. Differentiating PFAPA syndrome from monogenic periodic fevers. Pediatrics. 2009; 124(4): e721–728.

16. Amarilyo G, Rothman D, Manthiram K, Edwards KM, Li SC, Marshall GS, Yildirim­Toruner C, Haines K, Ferguson PJ, Lionetti G, Cherian J, Zhao Y, DeLaMora P, Syverson G, Nativ S, Twilt M, Michelow IC, Stepanovskiy Y, Thatayatikom A, Harel L, Akoghlanian S, Tucker L, Marques MC, Srinivasalu H, Propst EJ, Licameli GR, Dedeoglu F, Lapidus S; CARRA PFAPA Consensus Treatment Plan Workgroup. Consensus treatment plans for periodic fever, aphthous stomatitis, pharyngitis and adenitis syndrome (PFAPA): a framework to evaluate treatmentresponses from the childhood arthritis and rheumatologyresearch alliance (CARRA) PFAPA work group. Pediatr Rheumatol Online J. 2020; 18 (1): 31.

17. Gattorno M, Hofer M, Federici S for the Eurofever Registry and the Paediatric Rheumatology International Trials Organisation (PRINTO), et al. Classi cation criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases. 2019; 78: 1025­1032.

18. Hofer M, Pillet P, Cochard M­M, Berg S, Krol P, Kone­Paut I, Rigante D, Hentgen V, Anton J, Brik R, Neven B, Touitou I, Kaiser D, Duquesne A, Wouters C, Gattorno M. International periodic fever, aphthous stomatitis, pharyngitis, cervical adenitis syndrome cohort: description of distinct phenotypes in 301 patients. Rheumatology (Oxford). 2014; 53 (6): 1125–1129.

19. Tasher D, Stein M, Dalal I, Somekh E. Colchicine prophylaxis for frequent periodic fever, aphthous stomatitis, pharyngitis and adenitis episodes. Acta Paediatr. 2008; 97: 1090–1092.

20. Quintana­Ortega C, Seoane­Reula E, Fernández L, Camacho M, Olbrich P, Neth O, Murias S, Udaondo C, Remesal A, Calvo C, Alcobendas R. Colchicine treatment in children with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A multicenter study in Spain. Eur J Rheumatol. 2020; 8 (2): 73–78.

21. Abramson JS TJ, Givner LB. Possible role of tonsillectomy and adenoidectomy in children with recurrent fever and tonsillopharyngitis. Pediatr Infect Dis. 1989; 8 (2): 119–120.

22. Burton MJ, Pollard AJ, Ramsden JD, Chong LYe, Venekamp RP. Tonsillectomy for periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA). Cochrane Database Syst Rev. 2014; 9: CD008669.

23. Ter Haar N, Lachmann H, Ozen S, et al. Treatment of autoin ammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis. 2013; 72 (5): 678­685.

 

CLINICAL CASE

UDC 578.834.1:616.441-002-097

DOI: 10.20969/VSKM.2021.14(4).85-91

PDF download NEW COVID-19 CORONAVIRUS INFECTION IN A PATIENT WITH AUTOIMMUNE POLYGLANDULAR SYNDROME (clinical case)

IVANOVA LIUDMILA A., ORCID: 0000-0001-5302-3802; D. Med. Sci., professor, the Head of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(988)242-13-90, e-mail: endocrinkgmu@mail.ru

KOROL’ INNA V., ORCID: 0000-0002-3909-9007; C. Med. Sci., associate professor of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(918)414-44-19, e-mail: innakorol1@mail.ru

KOVALENKO JULIYA S., ORCID:0000-0002-7236-7341; С. Med. Sci., assistant of professor of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(952)813-17-96, e-mail: julendo@mail.ru

RUZHITSKAYA LIDIYA V., ORCID: 0000-0002-8809-7008; assistant of professor of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(918)671-56-05, e-mail: lida_ruz-7@mail.ru

SKIBITSKAYA MARIYA V., ORCID ID: 0000-0003-1908-1720; second year clinical resident of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(938)409-50-33, e-mail: skibitskaya_93@mail.ru

PETROVYKH VERONICA O., ORCID ID: 0000-0002-8773-2612; second year clinical resident of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(938)865-64-35, e-mail: nikusha.pet2403@yandex.ru

TANIN IVAN YU., ORCID:0000-0001-8883-3899; second year clinical resident of the Department of endocrinology of faculty of advanced training and professional specialist retraining of Kuban State Medical University, Russia, 350063, Krasnodar, Sedin str., 4, tel. +7(989)280-50-76, e-mail: Tanin2012ivan@mail.ru

Abstract. Background. More than half of those infected with the new coronavirus infection COVID­19 carry the disease in a mild or asymptomatic form. Patients over 60 years of age and those with comorbid chronic diseases, such as respiratory, cardiovascular, diabetes, oncological and autoimmune diseases, are susceptible to more severe forms of the disease. Aim. The aim of the study was to demonstrate the stages of clinical picture development, methods of diagnosis and treatment of the new coronavirus infection COVID­19. Material and methods. We present a clinical case of a new coronavirus infection COVID­19 in a 73­year­old patient with autoimmune polyglandular syndrome. Results and its discussion. Aggravating background represented by arrhythmic syndrome and autoimmune polyglandular syndrome contributed to the development of a severe form of new coronavirus infection COVID­19 in the patient. Complex multivector therapy aimed at pathogenetic and symptomatic treatment, according to the guidelines, in combination with magnesium and potassium medications, as well as immune­modulating therapy contributed to the patient’s recovery and rehabilitation. Conclusion. Treatment with glucocorticoids for new COVID­19 coronavirus infection signi cantly improves the outcome of the disease. At the same time, glucocorticoid therapy can lead to progression of arrhythmic syndrome, development of drug­induced hypercorticoidism, and «withdrawal» syndrome. Prevention and treatment of heart rhythm disturbances is the application of potassium and magnesium medications in suf cient doses. Gradual withdrawal of glucocorticoids over a long time under the supervision of an endocrinologist will help to restore the hypothalamic­pituitary­adrenal axis.

Key words: new coronavirus infection COVID­19, polyglandular autoimmune syndrome, glucocorticoids.

For reference: Ivanova LA, Korol IV, Kovalenko JuS, Ruzhitskaya LV, Skibitskaya MV, Petrovych VO, Tanin IYu. New coronavirus infection COVID­19 in a patient with polyglandular autoimmune syndrome (clinical case). The Bulletin of Contemporary Clinical Medicine. 2021; 14 (4): 85­91. DOI: 10.20969/VSKM.2021.14(4).85­91.

References

  1. Perez­ Saez J, et al. Serology­informed estimates of SARS­CoV­2 infection fatality risk in Geneva, Switzerland. The Lancet Infectious Diseases. 2020; 21 (4): 69­70.

  2. Fignani D, Licata G, Brusco N, et al. SARS­CoV­2 receptor Angiotensin I­Converting Enzyme type 2 (ACE 2) is expressed in human pancreatic β­cells and in the human pancreas microvasculature. bioRxiv. 2020; doi: https://doi. org/10.1101/2020.07.23.208041

  3. Marini DD, Uiller AP. Medicina kriticheskih sostoyanij [Medicine of critical states]. Izdatel’stvo: Meditsina [Publisher: Medicine]. 2000; 992 p.

  4. Ben Salem C, Hmouda H, Bouraoui K. Drug­induced hypokalaemia. Curr Drug Saf. 2009; 4 (1): 55–61.

  5. Ostroumova OD, Kochetkov AI, Klepikova MV. Lekar­ stvenno­inducirovannyj de cit elektrolitov; Chast’ vtoraya: Lekarstvenno­inducirovannaya gipomagniemiya [Drug­ induced electrolyte de ciency; Part two: Drug­induced hypomagnesemia]. Rossijskij medicinskij zhurnal [Russian medical journal]. 2020; 12: 36­48.

  6. Averin EE, Nikitin AE, Pozdnyak AO, et al. Prakticheskie aspekty diagnostiki i korrekcii kalij – i magnijde citnyh sostoyanij; Mnenie ekspertov [Practical aspects of the diagnosis and correction of potassium­magnesium de ciency states; Expert opinion]. Kardiologiya [Car­ diology]. 2020; 60 (2): 155–164.

  7. Ramírez E, Rossignol T, Campos AJ. Drug­induced life­threatening potassium disturbances detected by a pharmacovigilance program from laboratory signals. Eur J Clin Pharmacol. 2013; 69 (1): 97–110.

  8. Ivanova LA, Korol IV, Kovalenko YuS, et al. Razvitiye sindroma polikistoznykh yaichnikov u patsiyentki s klassicheskim sindromom vrozhdennoy disfunktsii kory nadpochechnikov [Development of polycystic ovary syndrome in patient with a classic variant of congenital adrenal dysfunction]. Kubanskiy nauchnyy meditsinskiy vestnik [Kuban Scienti c Medical Bulletin]. 2018; 7 (1): 1038­1042.

  9. NHS. Oxford University Hospitals. Guidelines for the Management of Hypomagnesaemia in Adult Clinical Haematology Patients. 2020; http://nssg.oxford­haema­ tology.org.uk/oxford/clinical­care/H­95­guidelines­for­ management­of­hypomagnesaemia­in­adult­clinical­haematology

 

ANNIVERSARIES

PDF download On the 60th anniversary of Andrey Yuryevich Anisimov, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Natural Sciences, Member of the editorial Board of the Journal «The Bulletin of Contemporary Clinical Medicine» P. 92